{"docstore/data": {"6f69c112-8f03-4ddb-8854-ffb17f62804c": {"__data__": {"id_": "6f69c112-8f03-4ddb-8854-ffb17f62804c", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. "}, "hash": "2fead966570b9d0f574d7b2ff71316a7eb45f4262419b452c600ed507856870f", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion. ", "start_char_idx": 0, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234": {"__data__": {"id_": "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f69c112-8f03-4ddb-8854-ffb17f62804c", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c09b1243cebbce529b32407b2392c3727fc10fb61fd7836733d8defdc0fc9520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa32a19c-7633-42a5-aeaa-3658b0e67427", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter. "}, "hash": "2afe41e798da0521bc586ed098e882e7269f92f76a40bd615ca86167ab4d2827", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 538, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa32a19c-7633-42a5-aeaa-3658b0e67427": {"__data__": {"id_": "fa32a19c-7633-42a5-aeaa-3658b0e67427", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd5c48959d41640f67011896f874e7473caed88e5d52e634da9d059820c1f38b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n"}, "hash": "cfd5f3fbf4afb801fc580ec9a29007013c5908432a163796860e73bf606abb5d", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter. ", "start_char_idx": 559, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d": {"__data__": {"id_": "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa32a19c-7633-42a5-aeaa-3658b0e67427", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe757901236494618ef7de0d0e323c9d34b0c5a9c3bd29ad49ef631abb8b3cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d690e74-07a8-47b4-a72b-2dacf8bd1eef", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. "}, "hash": "3e694a8c21501236fe5aea7f87043c9d518ca8c046ca16de41a0d43431917810", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "start_char_idx": 737, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d690e74-07a8-47b4-a72b-2dacf8bd1eef": {"__data__": {"id_": "9d690e74-07a8-47b4-a72b-2dacf8bd1eef", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ef15e50093ccab65e772d75dc67223025b4a18293818f7312d3b104bffa9fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e13e9bb8-bfa9-483b-9213-1555930281d0", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. "}, "hash": "a67cf7a0676f799e8949a0f31e255abd87d2f7c5d11c2f31bf3ca86854e2e898", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "start_char_idx": 883, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e13e9bb8-bfa9-483b-9213-1555930281d0": {"__data__": {"id_": "e13e9bb8-bfa9-483b-9213-1555930281d0", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d690e74-07a8-47b4-a72b-2dacf8bd1eef", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "408ea656625459b6709f01756b9e22ba71967a0e58997ddd8914309c4de2ae6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcdb157a-2a24-4a89-a233-fde9af9c7e42", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n"}, "hash": "9c0a708636e62c245456f6dbcae5519c6ad6d28763a55534fb6f6bdd923ee261", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "start_char_idx": 947, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcdb157a-2a24-4a89-a233-fde9af9c7e42": {"__data__": {"id_": "dcdb157a-2a24-4a89-a233-fde9af9c7e42", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e13e9bb8-bfa9-483b-9213-1555930281d0", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d17592540b6d000a8a960aea331a7d7475ab0958f6b8d3aa4d1a0763b286fc7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. "}, "hash": "ea84d186f75507474e1a6a59d2d3d4993cb69bfa42a8ca4f82d56f48b7a545b3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "start_char_idx": 1071, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a": {"__data__": {"id_": "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcdb157a-2a24-4a89-a233-fde9af9c7e42", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "177b3f66df0db52956ebec4514dac4f5ef4d1fe5990e7ca67086ee792e9b3d0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7417037a-f314-4e39-a284-2823f56bc62d", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "original_text": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "f6cf7c7b8f61307c620667b141c32a5989dbe31b79557bbebfc8c44cedc14781", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "start_char_idx": 1264, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7417037a-f314-4e39-a284-2823f56bc62d": {"__data__": {"id_": "7417037a-f314-4e39-a284-2823f56bc62d", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "original_text": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d14a681e5fe802ee6058c4fdde64be0c86c00d3d8546675929e58fdbb989565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. "}, "hash": "44c293fd8d0236b56bb028d797f987e0680f2a4f4952b277d2f30e7c0f71c7bc", "class_name": "RelatedNodeInfo"}}, "text": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1410, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d": {"__data__": {"id_": "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7417037a-f314-4e39-a284-2823f56bc62d", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "original_text": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90b0594e5bbaba922d08ce7e37f2e35a3a9d689c024b6249ed474045dc5c8534", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "Collis continued. "}, "hash": "641f81a5674a2ac964a5d56ae6a1f450fec9e78fc62250c94ad679bc24ef6286", "class_name": "RelatedNodeInfo"}}, "text": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "start_char_idx": 1726, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7": {"__data__": {"id_": "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7", "embedding": null, "metadata": {"window": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.25 to $8.50 to a range of $8.40 to $8.60, reflecting growth of 6 percent to 9 percent versus last fiscal year.\n \"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3688c503d4aa62ae8429b659e0510faf22825e371735cfa888b6c9e84f259ead", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ea926b7-160e-4858-8ac6-aae5af7613eb", "node_type": "1", "metadata": {"window": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n"}, "hash": "df25527bed4c844da91740c5789e2667afc38e34af366a19209046a9a1150887", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1924, "end_char_idx": 1942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ea926b7-160e-4858-8ac6-aae5af7613eb": {"__data__": {"id_": "3ea926b7-160e-4858-8ac6-aae5af7613eb", "embedding": null, "metadata": {"window": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen is driven by our purpose and we continue to leverage our scale and expertise to provide innovative solutions\nfor our partners.  Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15155b51a9699f3db71617691393f98da8ec74fe9b35abfb713c4d2ed88aa13f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "692f35d7-bb80-4681-af15-b826afafddcd", "node_type": "1", "metadata": {"window": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1"}, "hash": "d3862e8aa32182b6e9c5b113fe832578483a21735b55edcf32709e9c33cf2376", "class_name": "RelatedNodeInfo"}}, "text": "\"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "start_char_idx": 1942, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "692f35d7-bb80-4681-af15-b826afafddcd": {"__data__": {"id_": "692f35d7-bb80-4681-af15-b826afafddcd", "embedding": null, "metadata": {"window": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943ad70f0cd46f09990129c1d138a26b8a0f80420ff37f87e28ae483c4a5bd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ea926b7-160e-4858-8ac6-aae5af7613eb", "node_type": "1", "metadata": {"window": "Our strong performance in the December quarter and the improved outlook and financial guidance we are\nproviding for fiscal year 2021 are the result of our continued ability to execute and the resilience of our businesses,\" said Steven H.\nCollis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "\"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3770d535fdebcba401993d60d5b6873afb5897249d06b7149935fcb6b1b064b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ffcb98f-6650-46b8-8601-fa797536e2e4", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "ec821561b37d4af661d8c1d00aa21b4ecc8506301d691521f7b37c5be1d158bb", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "start_char_idx": 2148, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ffcb98f-6650-46b8-8601-fa797536e2e4": {"__data__": {"id_": "2ffcb98f-6650-46b8-8601-fa797536e2e4", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "692f35d7-bb80-4681-af15-b826afafddcd", "node_type": "1", "metadata": {"window": "\"As we move our business forward, we will continue to focus on execution excellence and supporting pharmaceutical innovation\nglobally to enable positive outcomes by facilitating market access,\" Mr.  Collis continued.  \"Our ongoing focus on long-term,\nsustainable growth and our purpose of being united in our responsibility to create healthier futures position us well to create\nsignificant value for all our stakeholders.\"\n First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "original_text": "First Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAPAdjust ed\n(Non-\nGAAP)\nRevenue $52.5B $52.5B\nGross Pr ofit $1.5B $1.4B\nOperating Expenses $905M $810M\nOperating Income $547M $617M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e 28.3% 22.0%\n1", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbae34a0e724dda6ded5ef916868d5fd01ae7f944690529c32fdde74142f548d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a7b60fc-c114-410e-9869-c197ca8ab42d", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "c822e54e423d8d42b8d542e030202be867b6be4fdcb46568a6228174799bf6b7", "class_name": "RelatedNodeInfo"}}, "text": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a7b60fc-c114-410e-9869-c197ca8ab42d": {"__data__": {"id_": "0a7b60fc-c114-410e-9869-c197ca8ab42d", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ffcb98f-6650-46b8-8601-fa797536e2e4", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8f76416f3ea961806faf5f695454c43a1fa0b251623e934b9097024a7b52389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1219bdb9-c295-48ed-a2a6-c56d54df34b0", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n"}, "hash": "feae1c950315db83248d49237adb492b16d2fc55a0d53fefebcac1ee8313d022", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 247, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1219bdb9-c295-48ed-a2a6-c56d54df34b0": {"__data__": {"id_": "1219bdb9-c295-48ed-a2a6-c56d54df34b0", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a7b60fc-c114-410e-9869-c197ca8ab42d", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f14397b15d84a5d1af557d5a1b44a5968f950c4c5f46d108150ade8c91f95ccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91df9e7a-64cc-49a0-8860-ab17d2b52a34", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n"}, "hash": "1ea6fd3907af6222effd22e517571316182763225d8487f32092f8ddb9e4db2a", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 339, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91df9e7a-64cc-49a0-8860-ab17d2b52a34": {"__data__": {"id_": "91df9e7a-64cc-49a0-8860-ab17d2b52a34", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1219bdb9-c295-48ed-a2a6-c56d54df34b0", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f26b0278d03e4ae71e2ace06c688097998c90ea950670c5a638eef85fa6676d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef290b9d-ad8b-4f72-b718-ff345ee420bd", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. "}, "hash": "ccbd47f9f1d45e038d858f7d913def1a748d01770808b1bbc46559cc1006af11", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "start_char_idx": 561, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef290b9d-ad8b-4f72-b718-ff345ee420bd": {"__data__": {"id_": "ef290b9d-ad8b-4f72-b718-ff345ee420bd", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91df9e7a-64cc-49a0-8860-ab17d2b52a34", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f25b4e5d80bb902a2535a1d8d5ac78b869d610f74b5f298c12d0bf429c1c19e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f7e0395-2c0e-4a1e-9871-49677cb799b4", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "original_text": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. "}, "hash": "2867d6dd466b30a1d8b0fe23cc453d0b001f2bdaf97d7d504f3c370e1dae47d2", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 873, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f7e0395-2c0e-4a1e-9871-49677cb799b4": {"__data__": {"id_": "2f7e0395-2c0e-4a1e-9871-49677cb799b4", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "original_text": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef290b9d-ad8b-4f72-b718-ff345ee420bd", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53505b93c7a6a7d36b2c66e0a08512045e180ab8ee88b66583576f718712dda1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "original_text": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n"}, "hash": "6cd6354a64f3e5eadc098143857ea934ece0a23e3a22c0cdf22b869830921e9f", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "start_char_idx": 1037, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb": {"__data__": {"id_": "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb", "embedding": null, "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "original_text": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f7e0395-2c0e-4a1e-9871-49677cb799b4", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "original_text": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f144934e06cf58e13fb0312c08f631a7a26ee29de28cafc5585eecffae0ad4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "453dbc99-d2b6-4381-9de9-45d7e19bf97d", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. "}, "hash": "e2912e640199f46cfbcc588346658622083d595c92b4fac058ec4924de6df874", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "start_char_idx": 1288, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "453dbc99-d2b6-4381-9de9-45d7e19bf97d": {"__data__": {"id_": "453dbc99-d2b6-4381-9de9-45d7e19bf97d", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "original_text": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4c7ed1d2e91844a8c14b22f3d3ab5f5ca6d6c6719b1cbbe67f376cce653d456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48356261-ac16-405b-b9fa-9fc0083072bc", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "original_text": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. "}, "hash": "98d876f3a3772c7590af3a2f1713dfa99f83aafa3411caf6a084898a8d209ae6", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "start_char_idx": 1406, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48356261-ac16-405b-b9fa-9fc0083072bc": {"__data__": {"id_": "48356261-ac16-405b-b9fa-9fc0083072bc", "embedding": null, "metadata": {"window": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "original_text": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "453dbc99-d2b6-4381-9de9-45d7e19bf97d", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2021 was $1.5 billion, an 18.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "original_text": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a2e3e434d7a946b3faadc2520fb04e3409e7d527879f86aa79f484b966df1bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11f2485d-d73a-4ae4-b834-d96dccf0e446", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "original_text": "This was partially offset by an increase in distribution, selling and\nadministrative costs. "}, "hash": "b4859ca2837a8de04b98653e9192489fa1a0107f6441615525d7134272fa7c0c", "class_name": "RelatedNodeInfo"}}, "text": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "start_char_idx": 1568, "end_char_idx": 1711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11f2485d-d73a-4ae4-b834-d96dccf0e446": {"__data__": {"id_": "11f2485d-d73a-4ae4-b834-d96dccf0e446", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "original_text": "This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48356261-ac16-405b-b9fa-9fc0083072bc", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by the increase in gross profit in Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year period, and\nan increase in gross profit in Other.  Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "original_text": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6aa6aa19bd09739248987ab079befcf43dcf50ea44de254e774c2ce2fb07a566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab4cb473-561e-4c12-95bf-0377bf84ee2a", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n"}, "hash": "cfce4d7e362c2d1c6109240ba4952c5d33cffad2638eaeee09d738dfe14f16c0", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "start_char_idx": 1711, "end_char_idx": 1803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab4cb473-561e-4c12-95bf-0377bf84ee2a": {"__data__": {"id_": "ab4cb473-561e-4c12-95bf-0377bf84ee2a", "embedding": null, "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11f2485d-d73a-4ae4-b834-d96dccf0e446", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 2.77 percent, an increase of 20 basis points\nfrom the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "original_text": "This was partially offset by an increase in distribution, selling and\nadministrative costs. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "995e1067c9e9c589da287e6a34fa43e51be48df0f37b6de0c16d20d46f0448a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f870365f-19ba-4706-8698-00937306a5ae", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "original_text": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. "}, "hash": "c81b08744c10c8eec874d76dc07bd675adab4fb217ab023ddefd178ff663b2f3", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "start_char_idx": 1803, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f870365f-19ba-4706-8698-00937306a5ae": {"__data__": {"id_": "f870365f-19ba-4706-8698-00937306a5ae", "embedding": null, "metadata": {"window": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "original_text": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab4cb473-561e-4c12-95bf-0377bf84ee2a", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2021, operating expenses were $905.0 million, compared to $967.8 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b2f7b9b048c81318439f3b561dde4aa1799e997697e32d1c7a470246130ffcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b67aca0-37a4-4b66-9fb6-607f3579d200", "node_type": "1", "metadata": {"window": "This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "original_text": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n"}, "hash": "99205b462117e2469422b07a50f4352e1d02a6dcdcbb61b8f9f13ad2f8934092", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "start_char_idx": 1974, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b67aca0-37a4-4b66-9fb6-607f3579d200": {"__data__": {"id_": "2b67aca0-37a4-4b66-9fb6-607f3579d200", "embedding": null, "metadata": {"window": "This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "original_text": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f870365f-19ba-4706-8698-00937306a5ae", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium assets recorded in the prior year quarter.  This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "original_text": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6410f3f264746ea7e7ba8cf9efdc6c2d6cd31d73a77387d79eec06d118cfa6e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5dc3506-b214-4bb6-a916-a5145eaf304d", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n"}, "hash": "cca7aaed323eaf4b68379b7e35cb95dc7a7447ea935bedd73c499d6f1ca9817c", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "start_char_idx": 2119, "end_char_idx": 2291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5dc3506-b214-4bb6-a916-a5145eaf304d": {"__data__": {"id_": "c5dc3506-b214-4bb6-a916-a5145eaf304d", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b67aca0-37a4-4b66-9fb6-607f3579d200", "node_type": "1", "metadata": {"window": "This was partially offset by an increase in distribution, selling and\nadministrative costs.  Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "original_text": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47efc752de7ea19b5989544c3c2b86cd6ced7acb996902601dda705d3afc1826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31c8c12e-526a-4b6d-a88c-64a9e995e7ff", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. "}, "hash": "083d469099085dca640211e7700c425bbeac392208bba20e055508ae00b1b7f8", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "start_char_idx": 2291, "end_char_idx": 2597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31c8c12e-526a-4b6d-a88c-64a9e995e7ff": {"__data__": {"id_": "31c8c12e-526a-4b6d-a88c-64a9e995e7ff", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5dc3506-b214-4bb6-a916-a5145eaf304d", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.72 percent,\ncompared to 2.02 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "354857ce87dc102ca44e62efe1204df597579125a563636b24f1a1f43c105b6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "original_text": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n"}, "hash": "bb30f27f2a77d9c6526ddaf13aa06d9837091790221a1f64ac98e41cc1065724", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "start_char_idx": 2597, "end_char_idx": 2747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db": {"__data__": {"id_": "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "original_text": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31c8c12e-526a-4b6d-a88c-64a9e995e7ff", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 first quarter, operating income increased to $547.2 million from $263.4 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "573c4aa5da52579325bfd0f9f8b9077f5dcc831430d75750764b55b2f6f57ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. "}, "hash": "9de2131cf39c3d1134e20e99853ce762ae301679894b145089a069983567ea0a", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "start_char_idx": 2747, "end_char_idx": 2853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e": {"__data__": {"id_": "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.04 percent in the first quarter of fiscal 2021, compared\nto 0.55 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "original_text": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8723c872de2aa1871dd3a3fc00b15cbe1d0f21de7698a063bba15bf4e7d2137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad3eb726-fd7c-4875-85cc-341bf7c8439a", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "original_text": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n"}, "hash": "b35044ce02b7a3b47b3fd8e004db85ba2e897f291463b8468d5f1adbab789abc", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "start_char_idx": 2853, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad3eb726-fd7c-4875-85cc-341bf7c8439a": {"__data__": {"id_": "ad3eb726-fd7c-4875-85cc-341bf7c8439a", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "original_text": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 first quarter, net interest expense of $33.6 million was up 8.4 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\npartially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa1b077784238ccdcb5ed2f1c089322064bb6a7c84e01456dcc5d5aa0a27f370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49b86af-b738-4694-a794-83f4e7dfe47e", "node_type": "1", "metadata": {"window": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n"}, "hash": "4ec02f9d370bc3db788f87e42a38efdd6273f768dc9ffc0e018955dc6e7bc75f", "class_name": "RelatedNodeInfo"}}, "text": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "start_char_idx": 3018, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49b86af-b738-4694-a794-83f4e7dfe47e": {"__data__": {"id_": "c49b86af-b738-4694-a794-83f4e7dfe47e", "embedding": null, "metadata": {"window": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad3eb726-fd7c-4875-85cc-341bf7c8439a", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 28.3 percent for the first quarter of fiscal 2021 compared to 18.7 percent in the\nprior year quarter.  The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "original_text": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb780252835cc68572586171e0680ce50ccc33f0b85479b4067a94b8de329e09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c46aae02-7e92-4594-b2e3-ff6ece49ca74", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "e3b90893f54a8dbaebc4ec46537853e430e012931c2c920da6d77d873f8d8232", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "start_char_idx": 3124, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c46aae02-7e92-4594-b2e3-ff6ece49ca74": {"__data__": {"id_": "c46aae02-7e92-4594-b2e3-ff6ece49ca74", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49b86af-b738-4694-a794-83f4e7dfe47e", "node_type": "1", "metadata": {"window": "The effective tax rate in the current quarter was higher primarily due to the impact of Swiss tax reform.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d38def12467ced4961d4b312e1537e609638d6486211cc370bafaa9cfba204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c96f93c3-dd33-4f5b-b33f-e91847e1fff9", "node_type": "1", "metadata": {"window": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n"}, "hash": "405b87e3bffa223910fe69608f2d8d003905dca4ee27d2f888d53de2fcd1ac09", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3415, "end_char_idx": 3532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c96f93c3-dd33-4f5b-b33f-e91847e1fff9": {"__data__": {"id_": "c96f93c3-dd33-4f5b-b33f-e91847e1fff9", "embedding": null, "metadata": {"window": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c46aae02-7e92-4594-b2e3-ff6ece49ca74", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.81 in the first quarter of fiscal 2021 compared to $0.90 in the\nprevious fiscal year\u2019s first quarter.  The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1202429245b7ba7fd498b3a4c3c4f50c8751f1cd37e4eafcad16e6d6cc8df5c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. "}, "hash": "60bc0423adbeaa813ce7be24af7b72107f25ba98832b1eef370aac9f15e2f3e1", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "start_char_idx": 3532, "end_char_idx": 3805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2": {"__data__": {"id_": "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c96f93c3-dd33-4f5b-b33f-e91847e1fff9", "node_type": "1", "metadata": {"window": "The increase was driven by higher operating income and partially offset by the higher\neffective tax rate.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d02c2f3a26dd9c83f8b93fcaa3956d7118b26f6e57748e55730286d1fb741a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3da4f95-4f87-4aa7-b981-a301f729254b", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n"}, "hash": "09c031355174d6fe87712d52729c53269c4c330ff64a41c002301af0ea535406", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "start_char_idx": 3805, "end_char_idx": 4061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3da4f95-4f87-4aa7-b981-a301f729254b": {"__data__": {"id_": "e3da4f95-4f87-4aa7-b981-a301f729254b", "embedding": null, "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2021 were 206.8\nmillion, a 0.3 percent decline versus the prior fiscal year first quarter primarily due to share repurchases, net of stock option\nexercises and restricted stock vesting.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9c2c41ecfce8acb9bc42e71181f39d6ff7d1a7f7caed8c3f71baa78921c9de1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "328694d0-c667-48e8-9f8f-278e4082c166", "node_type": "1", "metadata": {"window": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2"}, "hash": "5fc7d0b0c3a0c97d9f4f5df367d27bf17c7a4eb21e7c7caed8bf507de6c00104", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "start_char_idx": 4061, "end_char_idx": 4279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "328694d0-c667-48e8-9f8f-278e4082c166": {"__data__": {"id_": "328694d0-c667-48e8-9f8f-278e4082c166", "embedding": null, "metadata": {"window": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3407d48867840b01387d4009b46709febbd7797796c2246ea1e95333a1f5f2c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3da4f95-4f87-4aa7-b981-a301f729254b", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "631ba2cbf7209dd4b97fe0465acfa39b5312b400eeb8a19c1da94a6f56ff3d02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beb21146-5588-4e02-a365-58585dd278ad", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "original_text": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses. "}, "hash": "29dfd4379b2956dfb1cd8952287928887ed017432af6d14dbc1aa047b7e21c99", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "start_char_idx": 4279, "end_char_idx": 4408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beb21146-5588-4e02-a365-58585dd278ad": {"__data__": {"id_": "beb21146-5588-4e02-a365-58585dd278ad", "embedding": null, "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "original_text": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "328694d0-c667-48e8-9f8f-278e4082c166", "node_type": "1", "metadata": {"window": "In the first quarter of fiscal 2021, revenue was\n$52.5 billion, up 9.7 percent compared to the same quarter in the previous fiscal year, reflecting a 9.7 percent increase in\nPharmaceutical Distribution Services revenue and an 11.1 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 first quarter was $1.4 billion, which was up 14.8 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2021 first quarter, an increase of 12\nbasis points when compared to the prior year quarter due to an increase in specialty product sales.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2021, adjusted operating expenses were $809.6 million, an increase\n2", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b68e492523f01d1f6752d9252173c4d5103ae4e4bac5deb539d88178e5934562", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bf4c762-efff-4a5c-832d-cf950aa38e6f", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n"}, "hash": "33f8d001da93b5839ae44a9f51e71de0a713bc8e2e68545e254804a1d43acca1", "class_name": "RelatedNodeInfo"}}, "text": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bf4c762-efff-4a5c-832d-cf950aa38e6f": {"__data__": {"id_": "4bf4c762-efff-4a5c-832d-cf950aa38e6f", "embedding": null, "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beb21146-5588-4e02-a365-58585dd278ad", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "original_text": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1ada4f04cb1b6904f08f0dfd9e3f85c0ca1384502100b0fcc010cbedc719a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8be1e17-73f7-4b90-84eb-81b2174b2172", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other. "}, "hash": "eef82e302aa4d9dd7e107e36e92985ea07d33234d4f3798d5cc0b76e059b8dd7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n", "start_char_idx": 137, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8be1e17-73f7-4b90-84eb-81b2174b2172": {"__data__": {"id_": "f8be1e17-73f7-4b90-84eb-81b2174b2172", "embedding": null, "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bf4c762-efff-4a5c-832d-cf950aa38e6f", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48e90401154d11e537471c5e38e5b987fa0b3d657ecca2bd4ee99714d0ec7378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fdb71b9-b7ec-4c08-815e-064d4f6ec745", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n"}, "hash": "23e4cd338c693961c7f150a3155c530a7969c3a3baf840af650a46c3d4d1edf6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other. ", "start_char_idx": 306, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fdb71b9-b7ec-4c08-815e-064d4f6ec745": {"__data__": {"id_": "9fdb71b9-b7ec-4c08-815e-064d4f6ec745", "embedding": null, "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8be1e17-73f7-4b90-84eb-81b2174b2172", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1945488958de201a320f57c26a8493f9bd332779951c0bc0c02b56c5135e9ea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4224b25-439e-48fc-95c1-a1f11acb6450", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "6f4c4131ba45465151d6024d810656235a3722021428b8ca07827d1b41c72573", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "start_char_idx": 613, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4224b25-439e-48fc-95c1-a1f11acb6450": {"__data__": {"id_": "a4224b25-439e-48fc-95c1-a1f11acb6450", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fdb71b9-b7ec-4c08-815e-064d4f6ec745", "node_type": "1", "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f443772a7b1acbab784a634875ec3e13b8118226e1601d93904df965fd4fe4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1149b373-3242-4ac3-9f05-ef8cf343ce5f", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n"}, "hash": "7f9a39d3e15ae3c86b0bd4a6aae695ed48c0b4789857e319de3cc3a4f5359c9c", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 789, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1149b373-3242-4ac3-9f05-ef8cf343ce5f": {"__data__": {"id_": "1149b373-3242-4ac3-9f05-ef8cf343ce5f", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4224b25-439e-48fc-95c1-a1f11acb6450", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6e428625d85f387e501e5db0c8ba58c7f4f5476ce3cf5d49ebf5d4cb84c7a77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4da8643-2e9b-4e89-a34c-208c098af54a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n"}, "hash": "d6fd17b03ad83b4404d542e2f4c125c2a94ef36e32c6433e39afaa1c886babfb", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "start_char_idx": 888, "end_char_idx": 1170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4da8643-2e9b-4e89-a34c-208c098af54a": {"__data__": {"id_": "a4da8643-2e9b-4e89-a34c-208c098af54a", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1149b373-3242-4ac3-9f05-ef8cf343ce5f", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "201ddbc8ea12aa14992fca6cae87b31556c2a1813438548c64828811a0b5627b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cabdf4b-ef78-4533-9829-0000e095fd16", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n"}, "hash": "2bc077709848aff0420284057a3a4ee8a21e9a3c09b19c1b089d6124b691d439", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "start_char_idx": 1170, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cabdf4b-ef78-4533-9829-0000e095fd16": {"__data__": {"id_": "6cabdf4b-ef78-4533-9829-0000e095fd16", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4da8643-2e9b-4e89-a34c-208c098af54a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96797d4a2f7952ee67f6924be235a1eeec96043af0372093ae9c9d5c75048e86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44bc8c7b-822e-49cf-b262-6884e83fa12d", "node_type": "1", "metadata": {"window": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "62c2e0df7fbf21ef9f21a54d1ac753df651c577695f675f178a94d41fc5220f8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "start_char_idx": 1338, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44bc8c7b-822e-49cf-b262-6884e83fa12d": {"__data__": {"id_": "44bc8c7b-822e-49cf-b262-6884e83fa12d", "embedding": null, "metadata": {"window": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cabdf4b-ef78-4533-9829-0000e095fd16", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8745e7405f4a4202b3c74865aefbe38a87f180e20a71485c6225a2798cc8b862", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n"}, "hash": "bce7f723ceca064d018d2a6e9f6436a31d5ef81f4a2627b56c7c1a0a9665f77b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 1593, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e": {"__data__": {"id_": "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44bc8c7b-822e-49cf-b262-6884e83fa12d", "node_type": "1", "metadata": {"window": "In the fiscal 2021 first\nquarter, net interest expense of $33.6 million was up 8.4 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was partially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b877af485d591938a73ea3674581d3e5c6335079141220bd4ac705807d4c0df2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d90bf804-aa49-48b7-bab1-147f41080076", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. "}, "hash": "2e53d323e1828be9d94d6c19c3e5a671d2707aaf69601da35262932b672ec351", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "start_char_idx": 1703, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d90bf804-aa49-48b7-bab1-147f41080076": {"__data__": {"id_": "d90bf804-aa49-48b7-bab1-147f41080076", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 22.0 percent for the first quarter of fiscal 2021 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0af099f42ee2fc3107621854df51f4bcf2a1a1c5ba3ee847dc3e8bb3dfce00c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "9370c4352d0bfbdc5741f0e236719518be7d65b036939918c3e1b3af1e66f43b", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "start_char_idx": 1965, "end_char_idx": 2297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1": {"__data__": {"id_": "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d90bf804-aa49-48b7-bab1-147f41080076", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 23.9 percent to $2.18 in the first quarter of\nfiscal 2021 compared to $1.76 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34ba444463c3f913b8088f2332390519b73ffac39b6f99ad34ec20205c3c33cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f46a392-5691-4f94-9a2c-032e1f6d1e88", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. "}, "hash": "920b1624218606f87739cb708f06f5cb86b64fb2603f05d7ea2974bd5ffec3c2", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 2297, "end_char_idx": 2502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f46a392-5691-4f94-9a2c-032e1f6d1e88": {"__data__": {"id_": "5f46a392-5691-4f94-9a2c-032e1f6d1e88", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "478a4b8be2c1c9c3b1d8801ef0d79fca7e78bb3fc3f9e5eab535bb8a68ccc036", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b52b6ae-8856-4745-8502-342145c4e9a0", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "original_text": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n"}, "hash": "bfaaf618b1099025aa8f3ac7f8fa55a894f49a2b2776ea4fde3600d3b7765fa7", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "start_char_idx": 2502, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b52b6ae-8856-4745-8502-342145c4e9a0": {"__data__": {"id_": "1b52b6ae-8856-4745-8502-342145c4e9a0", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "original_text": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f46a392-5691-4f94-9a2c-032e1f6d1e88", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2021 were 206.8 million, a 0.3 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases, net of stock option exercises and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "345039644a3d942b858038ede26ae03ccd8df1b55585fa856dda683a4e527589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6398591-5d14-49c1-b8ec-1b8b29836f55", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "original_text": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. "}, "hash": "9890afa981b9385f8453af9b9c1c58a3ee092fabe151004574440f98da44dff9", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "start_char_idx": 2832, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6398591-5d14-49c1-b8ec-1b8b29836f55": {"__data__": {"id_": "f6398591-5d14-49c1-b8ec-1b8b29836f55", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "original_text": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b52b6ae-8856-4745-8502-342145c4e9a0", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "original_text": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "648857727519f26de1e603fa6acb22785cdc4d271cb650b7a52e3be17d219d9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e2c3695-5340-4a76-af0b-477098cd4360", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "original_text": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n"}, "hash": "86a67b778b89a141b4566ebc207a34e31d0667590f68c6160d46e48fb9720925", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "start_char_idx": 3053, "end_char_idx": 3288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e2c3695-5340-4a76-af0b-477098cd4360": {"__data__": {"id_": "7e2c3695-5340-4a76-af0b-477098cd4360", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "original_text": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6398591-5d14-49c1-b8ec-1b8b29836f55", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "original_text": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f71ab5d3b4d8fa4ddccfeb541af0ca401bd5ed1e3f2fb11700b1314518aec4ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67", "node_type": "1", "metadata": {"window": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. "}, "hash": "b8129ce4911b35903089f04d03847fca2f3e75dbd85c87d0b07bd4a049fa37be", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "start_char_idx": 3288, "end_char_idx": 3447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67": {"__data__": {"id_": "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67", "embedding": null, "metadata": {"window": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e2c3695-5340-4a76-af0b-477098cd4360", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $50.5 billion, an increase of 9.7 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and organic growth of some of its\nlargest customers.  Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "original_text": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b434a5b7e243a836edf6bc671c6137098ef4ac33da5861d8c0758ac27a6558e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "442d84bf-04ec-46c9-a865-46816f1ac4f7", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "original_text": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n"}, "hash": "56034c4ec88ab8f5d65fc1e55decf0baa3623bef549867b12d9529237b586053", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "start_char_idx": 3447, "end_char_idx": 3715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "442d84bf-04ec-46c9-a865-46816f1ac4f7": {"__data__": {"id_": "442d84bf-04ec-46c9-a865-46816f1ac4f7", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "original_text": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67", "node_type": "1", "metadata": {"window": "Segment operating income of $496.1 million in the first quarter of fiscal 2021 was up 26.6 percent compared to\nthe same period in the previous fiscal year, due to higher gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da0437cd53ade521b79d0ceeba592f345e0551a5d9ecefc8851adfe2089d4cfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b74692ba-ec0a-4ea5-9f13-4095f9e59582", "node_type": "1", "metadata": {"window": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S. ", "original_text": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n"}, "hash": "599c77d6f6a4068be8fc2865489ec133df51b504111857e0375f96e4a01e9ad0", "class_name": "RelatedNodeInfo"}}, "text": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "start_char_idx": 3715, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b74692ba-ec0a-4ea5-9f13-4095f9e59582": {"__data__": {"id_": "b74692ba-ec0a-4ea5-9f13-4095f9e59582", "embedding": null, "metadata": {"window": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S. ", "original_text": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "442d84bf-04ec-46c9-a865-46816f1ac4f7", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the first quarter of fiscal 2021, an increase of 11.1 percent compared to the same period in the\nprior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "original_text": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd07ca6b00ef1aac1ea56f1de751f67c4024b24f3d72965d71975ba94cf03265", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd4531b7-9b2e-4647-b071-0da772f1fba5", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. "}, "hash": "8f216252573d67f1252fbc50e2ee5176a6176e1de78fd9ab14886f3cd676a0fb", "class_name": "RelatedNodeInfo"}}, "text": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "start_char_idx": 3850, "end_char_idx": 4006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd4531b7-9b2e-4647-b071-0da772f1fba5": {"__data__": {"id_": "dd4531b7-9b2e-4647-b071-0da772f1fba5", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b74692ba-ec0a-4ea5-9f13-4095f9e59582", "node_type": "1", "metadata": {"window": "Operating income in Other increased\n16.4 percent to $121.6 million in the first quarter of fiscal 2021 due to the strong performance of MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S. ", "original_text": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07ce23cf597611eb383f580bbd3fabf036a9aa9ae51123080f5cf48e374622c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e", "node_type": "1", "metadata": {"window": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n"}, "hash": "ee03cf776bdfa5640c65207bf60f825bc951191a84c510f5239cfffc0a5321fd", "class_name": "RelatedNodeInfo"}}, "text": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "start_char_idx": 4006, "end_char_idx": 4196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e": {"__data__": {"id_": "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e", "embedding": null, "metadata": {"window": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd4531b7-9b2e-4647-b071-0da772f1fba5", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which AmerisourceBergen will\nacquire the majority of Walgreens Boots Alliance\u2019s Alliance Healthcare businesses for approximately $6.5 billion.  This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b477bd75efb27488e9bde6c8291c6d590af90e8900589c67fdc8d23a68f1bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6bc1dff-a395-4849-9aa8-4b99ae582c2a", "node_type": "1", "metadata": {"window": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "AmerisourceBergen reached an agreement with the U.S. "}, "hash": "b8328a9f5ed8dc47f9b8ebb7472307e77a0a1dd1c7acb3cb91c381c6af9988e6", "class_name": "RelatedNodeInfo"}}, "text": "As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "start_char_idx": 4196, "end_char_idx": 4447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6bc1dff-a395-4849-9aa8-4b99ae582c2a": {"__data__": {"id_": "d6bc1dff-a395-4849-9aa8-4b99ae582c2a", "embedding": null, "metadata": {"window": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "AmerisourceBergen reached an agreement with the U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e", "node_type": "1", "metadata": {"window": "This\nacquisition is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals.\n In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6383549be2d2c71b7420a799740a47a90e6452b82e6498d3fc09bd3d64bcdbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d014538-f3bb-4dc9-aff6-8d9c74f97361", "node_type": "1", "metadata": {"window": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Centers for Disease Control and Prevention (CDC) to include Good\n3"}, "hash": "5e599ce2b3244c14d850a5553832f289e74974c4f719c755c3f4746c1c889ccc", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen reached an agreement with the U.S. ", "start_char_idx": 4447, "end_char_idx": 4500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d014538-f3bb-4dc9-aff6-8d9c74f97361": {"__data__": {"id_": "6d014538-f3bb-4dc9-aff6-8d9c74f97361", "embedding": null, "metadata": {"window": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Centers for Disease Control and Prevention (CDC) to include Good\n3", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d239bd7ef9b38f84bbb20fb3b2c1429c05fdd9778c9a5804942cffd86fd653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6bc1dff-a395-4849-9aa8-4b99ae582c2a", "node_type": "1", "metadata": {"window": "In addition to this transaction, the two companies agreed to strengthen their strategic partnership by extending and\nexpanding their commercial agreements.\n Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "AmerisourceBergen reached an agreement with the U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ed70bacc4bfd004e384abc975030801a4db134102d6f0e54015a7eae04a667a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fda1dbb-fb44-43ef-a357-4a80759919f9", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "original_text": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination. "}, "hash": "e8380972bc36dcdc36d6b53ac101286a2494a9ccefc94b8e2b55558de7c01310", "class_name": "RelatedNodeInfo"}}, "text": "Centers for Disease Control and Prevention (CDC) to include Good\n3", "start_char_idx": 4500, "end_char_idx": 4566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fda1dbb-fb44-43ef-a357-4a80759919f9": {"__data__": {"id_": "5fda1dbb-fb44-43ef-a357-4a80759919f9", "embedding": null, "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "original_text": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d014538-f3bb-4dc9-aff6-8d9c74f97361", "node_type": "1", "metadata": {"window": "Innomar Strategies, AmerisourceBergen\u2019s Canadian operations business unit, reached an agreement with the Government of\nCanada to support the distribution of COVID-19 vaccines across Canada.  As part of the agreement, Innomar is working with\nFedEx Express Canada to provide an end-to-end logistics solution that protects product viability throughout transport and\nenables safe and timely vaccine administration in each province and territory.\n AmerisourceBergen reached an agreement with the U.S.  Centers for Disease Control and Prevention (CDC) to include Good\n3", "original_text": "Centers for Disease Control and Prevention (CDC) to include Good\n3", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f907e96339ac38fd8f2205a39a1887c6861ed0e054aba5e91b0b8119f9579d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7ecd1b1-5f92-470a-8809-029d137031d0", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "original_text": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n"}, "hash": "cf067c38b6045d079761ed93c6d4b76ff84adda71934816fb9c48d13d427f4fc", "class_name": "RelatedNodeInfo"}}, "text": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination. ", "start_char_idx": 0, "end_char_idx": 126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7ecd1b1-5f92-470a-8809-029d137031d0": {"__data__": {"id_": "a7ecd1b1-5f92-470a-8809-029d137031d0", "embedding": null, "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "original_text": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fda1dbb-fb44-43ef-a357-4a80759919f9", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "original_text": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42292c3c375fa8fb65089f4d0fb96cb22f6e6a25a5fd32a6c2f306b243d00cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6628ecf-b882-4912-9221-43e529f3e0ac", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "original_text": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n"}, "hash": "40aa13c60db14a10635c493a7ec7b90362e0e39946f789f3fb5ad9fff0565f20", "class_name": "RelatedNodeInfo"}}, "text": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n", "start_char_idx": 126, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6628ecf-b882-4912-9221-43e529f3e0ac": {"__data__": {"id_": "e6628ecf-b882-4912-9221-43e529f3e0ac", "embedding": null, "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "original_text": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7ecd1b1-5f92-470a-8809-029d137031d0", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "original_text": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2abf5323ce7f7dcb52ea6db8b48cb75c9768535c81b1cdb2e4f226bc3de9e38c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4454308a-0f3d-473f-a59a-12ce7f85c7d5", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "original_text": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n"}, "hash": "0532acbb709c66766812269c9683b1f30c4138e9bfc07d0bebcf33e2c309ebc8", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n", "start_char_idx": 328, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4454308a-0f3d-473f-a59a-12ce7f85c7d5": {"__data__": {"id_": "4454308a-0f3d-473f-a59a-12ce7f85c7d5", "embedding": null, "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "original_text": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6628ecf-b882-4912-9221-43e529f3e0ac", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "original_text": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed5f25d7914bc192f9cbcf49e433e1912f8394389591f7e3cb2c686dd39150d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "697b6516-3e39-4429-8309-8044f55ebe9a", "node_type": "1", "metadata": {"window": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. "}, "hash": "35295399fdbebb38119d417ff1fc65c255cd5011178533608d39441d18837e9c", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "start_char_idx": 475, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "697b6516-3e39-4429-8309-8044f55ebe9a": {"__data__": {"id_": "697b6516-3e39-4429-8309-8044f55ebe9a", "embedding": null, "metadata": {"window": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4454308a-0f3d-473f-a59a-12ce7f85c7d5", "node_type": "1", "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "original_text": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d6d281b597a5066b20e505660052be9db5a8cbccb30e1f4936d89e7fad57582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9babbc5a-e87d-4626-a360-f5bc6572ed6a", "node_type": "1", "metadata": {"window": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n"}, "hash": "3a35b17ea10aade7ada5740859bbf63b6f916010be4b0c648df13f34e0376a37", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "start_char_idx": 648, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9babbc5a-e87d-4626-a360-f5bc6572ed6a": {"__data__": {"id_": "9babbc5a-e87d-4626-a360-f5bc6572ed6a", "embedding": null, "metadata": {"window": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "697b6516-3e39-4429-8309-8044f55ebe9a", "node_type": "1", "metadata": {"window": "To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a85a2006798a5b46fe3a47dcb404aad6e9bbf586e4a3d9e3a75ade41d7d2d45c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed", "node_type": "1", "metadata": {"window": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n"}, "hash": "437cc58827a6971cc84724974ace14d67bdef29d16f6357d2569135817422be3", "class_name": "RelatedNodeInfo"}}, "text": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "start_char_idx": 792, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed": {"__data__": {"id_": "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed", "embedding": null, "metadata": {"window": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9babbc5a-e87d-4626-a360-f5bc6572ed6a", "node_type": "1", "metadata": {"window": "AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "049eff125a14bbb6c4c9af05487fcac143142032f46a1a3003fcdd305c89647c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d644ed76-c4e3-47e1-b28f-7369c219b51d", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "5a2b013c04e8edfb7114228ae0fb9dd5a14497617920c1cb075be3f936a0a30a", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "start_char_idx": 991, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d644ed76-c4e3-47e1-b28f-7369c219b51d": {"__data__": {"id_": "d644ed76-c4e3-47e1-b28f-7369c219b51d", "embedding": null, "metadata": {"window": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed", "node_type": "1", "metadata": {"window": "AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da98f2cac5ca852fd63cc26fde8427e5a5ef151cc84155661e802097aaf8e428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5e5d013-fd50-4fce-84ed-b8af97244d4a", "node_type": "1", "metadata": {"window": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "daebf1f9d77dc5b214cf993c8c0fec465a10c4321cb6b0b8bf1dba235ca93271", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1233, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5e5d013-fd50-4fce-84ed-b8af97244d4a": {"__data__": {"id_": "d5e5d013-fd50-4fce-84ed-b8af97244d4a", "embedding": null, "metadata": {"window": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d644ed76-c4e3-47e1-b28f-7369c219b51d", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced it reached another environmental sustainability milestone by earning a B on the 2020 CDP\nClimate Change Disclosure.  The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b7dccd14b4d2053a47ef17a3b1ce80da285b0b00f1b5737b058e5e4bae10655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7857981-5452-4e12-9ef5-9bab4fe6fa35", "node_type": "1", "metadata": {"window": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. "}, "hash": "d797aecbf8a0808d4d3f01894ce0d63c7426ba46b238f6e0fdfd8b160711ec1d", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1477, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7857981-5452-4e12-9ef5-9bab4fe6fa35": {"__data__": {"id_": "b7857981-5452-4e12-9ef5-9bab4fe6fa35", "embedding": null, "metadata": {"window": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5e5d013-fd50-4fce-84ed-b8af97244d4a", "node_type": "1", "metadata": {"window": "The CDP assesses companies on the comprehensiveness of their disclosure, awareness and\nmanagement of environmental risks and demonstration of best practices associated with environmental leadership.\n AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fb1ce2677e1e26aca46fb7a5d995f23a563e5a96ea16a6123c59b2feaa3f456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cf4b884-4421-4078-9ee4-151813c0660e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. "}, "hash": "63a72c8068fb55214c209d73a19022a0b029d7b2a7855e9af98c3ec952292d9e", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "start_char_idx": 1609, "end_char_idx": 1818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cf4b884-4421-4078-9ee4-151813c0660e": {"__data__": {"id_": "9cf4b884-4421-4078-9ee4-151813c0660e", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7857981-5452-4e12-9ef5-9bab4fe6fa35", "node_type": "1", "metadata": {"window": "AmerisourceBergen unveiled a new company brand, including a new logo, website and renewed design, all of which reflect\nthe differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9107d2148686e478cec4de37132ab443ca371d5177291bd7f758a8c1de2bdf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54400107-fb68-4ead-b71b-9adb708c45f1", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "partnership announced in January 2021. "}, "hash": "b501720b0ebdd220c81534d5c78d75291113d7a8b1bea3aa44a13ceab1924d14", "class_name": "RelatedNodeInfo"}}, "text": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "start_char_idx": 1818, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54400107-fb68-4ead-b71b-9adb708c45f1": {"__data__": {"id_": "54400107-fb68-4ead-b71b-9adb708c45f1", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "partnership announced in January 2021. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cf4b884-4421-4078-9ee4-151813c0660e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bad6be80025f21d5b044987f2a5be2b442d131fd6786534ecc3d0722d19116b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "original_text": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n"}, "hash": "f2bc2bd990400ef270e947aa37e92b624f75c64f42e8b248b611d0a794db1f0c", "class_name": "RelatedNodeInfo"}}, "text": "partnership announced in January 2021. ", "start_char_idx": 1983, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010": {"__data__": {"id_": "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "original_text": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54400107-fb68-4ead-b71b-9adb708c45f1", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "partnership announced in January 2021. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eb794c07562f475f99292e723ba3aae6f9b43a6fd84bc74a910addfddbb21a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1154bdff-19dc-4a94-a2fb-d6624d64aa1c", "node_type": "1", "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n"}, "hash": "43396138b9d0c023e95c85a386dc9820c8b5c26f10585dec6d81c3ac2bf46533", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "start_char_idx": 2022, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1154bdff-19dc-4a94-a2fb-d6624d64aa1c": {"__data__": {"id_": "1154bdff-19dc-4a94-a2fb-d6624d64aa1c", "embedding": null, "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "original_text": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12cc269049d323b23f015e07cd6caabf9809bc7e1d5c3570e513468821c17857", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca5ace25-441d-4f28-8d77-27dc3d72b637", "node_type": "1", "metadata": {"window": "partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n"}, "hash": "d1944d5dac9b6bcae58a1d3dd7a5b7390b877186d89f3a63f7bfd2c4222df2b8", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "start_char_idx": 2255, "end_char_idx": 3052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca5ace25-441d-4f28-8d77-27dc3d72b637": {"__data__": {"id_": "ca5ace25-441d-4f28-8d77-27dc3d72b637", "embedding": null, "metadata": {"window": "partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1154bdff-19dc-4a94-a2fb-d6624d64aa1c", "node_type": "1", "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed Alliance Healthcare\nacquisition or any incremental growth from the expanded U.S.  partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12d961eed0d93f8a76da17bff55f95700cb045f02dc9da2255944b1ef05d7c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3544bf7b-bf7b-4831-b4d6-060344f97e87", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n"}, "hash": "f1fd308c50ffaea5571950cfe31fdc2144185f9a8814f8aefff9bf2cae475566", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "start_char_idx": 3052, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3544bf7b-bf7b-4831-b4d6-060344f97e87": {"__data__": {"id_": "3544bf7b-bf7b-4831-b4d6-060344f97e87", "embedding": null, "metadata": {"window": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca5ace25-441d-4f28-8d77-27dc3d72b637", "node_type": "1", "metadata": {"window": "partnership announced in January 2021.  The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f396cc32ff676ee70ec330de8506f478c185957780debbc86694a1c069e7cfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "db7a095f4790e6edcad627fe85c39d20407d38307993355d08e955ee4fc29e6d", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "start_char_idx": 3180, "end_char_idx": 3392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2": {"__data__": {"id_": "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3544bf7b-bf7b-4831-b4d6-060344f97e87", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the high-single digit percent range, up from the mid-single digit percent range; and\nAdjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.\n Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d56324ec56a1e4f63e405c3e9b1ec23969518f2ad1304051b92785a2dc953d44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30d21c16-4e84-4771-b69a-9ae86bab8d53", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "ET on February 4, 2021. "}, "hash": "789c5b55948e12ba3603fddd735806038fcf549e8ccbfe393ff35185f070af7e", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 3392, "end_char_idx": 3507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30d21c16-4e84-4771-b69a-9ae86bab8d53": {"__data__": {"id_": "30d21c16-4e84-4771-b69a-9ae86bab8d53", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "ET on February 4, 2021. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent\nrange;\nAdjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range;\nPharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from\nthe mid-single digit percent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income\ngrowth in the mid- to high-single digit percent range, up from the mid-single digit percent range;\nWeighted average shares to be approximately 207 million, narrowed from the previous expectation of between 206 and 207\nmillion for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b556b992e7cdc15258e0ce3bcff02e14742b2cadbf2a931babfbbab6e3149e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18e89691-7467-4070-b609-0de488c8bbf1", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "cedb7405ceb8c70d28fdd3ed85c723a637340d4f92eb4c65fc2c3ceb9924fb62", "class_name": "RelatedNodeInfo"}}, "text": "ET on February 4, 2021. ", "start_char_idx": 3507, "end_char_idx": 3531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18e89691-7467-4070-b609-0de488c8bbf1": {"__data__": {"id_": "18e89691-7467-4070-b609-0de488c8bbf1", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30d21c16-4e84-4771-b69a-9ae86bab8d53", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "ET on February 4, 2021. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c76b28d5b189af92ec0c3413ae721c1d0cb2e92a3063a2a387ec6688fb6c2b09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86be27aa-3e4a-4c6c-a17f-3d4365367925", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4"}, "hash": "b2df0eaae039bac6fe8270958ea7ac455ace5a62de2019535cbfca4e7836028d", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 3531, "end_char_idx": 3648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86be27aa-3e4a-4c6c-a17f-3d4365367925": {"__data__": {"id_": "86be27aa-3e4a-4c6c-a17f-3d4365367925", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bd40f54af4ed0bc5b955fe3d3a221dd7450c31c798469990cc7a802438881", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18e89691-7467-4070-b609-0de488c8bbf1", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable March 1, 2021, to\nstockholders of record at the close of business on February 12, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f35528dc5001dc7460006964ec6d098d2af2c6f4f37a61f3b1efed601ce803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d825f28-28b6-41b5-a503-82ea206393a6", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "The dial-in number for the live call will be (844) 808-6694. "}, "hash": "9281b15dd0073ac4a90bb94c7f467ef6bfaf96f52dba3b4061f0f8eef67c81b3", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "start_char_idx": 3648, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d825f28-28b6-41b5-a503-82ea206393a6": {"__data__": {"id_": "9d825f28-28b6-41b5-a503-82ea206393a6", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "The dial-in number for the live call will be (844) 808-6694. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86be27aa-3e4a-4c6c-a17f-3d4365367925", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\n4", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1db2d1194aee5dc0a41384c493f53794c1e1a6bb7644b63a6d1c17bfa5b0979f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af979747-1541-4a63-b886-80b942b5e7dd", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. "}, "hash": "a18e8920c6890faceacaa54315210309f93b3a37bf19dc734988dcd81c637d77", "class_name": "RelatedNodeInfo"}}, "text": "The dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 0, "end_char_idx": 61, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af979747-1541-4a63-b886-80b942b5e7dd": {"__data__": {"id_": "af979747-1541-4a63-b886-80b942b5e7dd", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d825f28-28b6-41b5-a503-82ea206393a6", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "The dial-in number for the live call will be (844) 808-6694. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d613ef1722ec6bcded8351e0fbe59b67a1bbe332aaf3043390fb990b9e34fb55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ab0a858-f5d0-4f9d-9649-2513b3934861", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "fa95325c027a991a6b8bd82edcb1636254be7e4af8a6559cce6a7056c2456a28", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial +1 (412) 317-5282. ", "start_char_idx": 61, "end_char_idx": 117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ab0a858-f5d0-4f9d-9649-2513b3934861": {"__data__": {"id_": "0ab0a858-f5d0-4f9d-9649-2513b3934861", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af979747-1541-4a63-b886-80b942b5e7dd", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e52f2d8d70c574f0e4b03471c2eb3ae0e2753133092a0e627d92168a162187a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32129d5e-5441-400c-ad87-d3e6663675a3", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "760a249d9567fbd2fcf87acf3eb88086e82b2bac799ec7b8f7235b1688bc1a08", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 117, "end_char_idx": 145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32129d5e-5441-400c-ad87-d3e6663675a3": {"__data__": {"id_": "32129d5e-5441-400c-ad87-d3e6663675a3", "embedding": null, "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ab0a858-f5d0-4f9d-9649-2513b3934861", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66c94b80419cc50e2498a9f604d0bb0172b517d221344ef93c9e0465169f6823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "977e52b469423f96d46f5da5cce93b4e56c7a608fe5b6815a463b36b0c95f305", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 145, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be": {"__data__": {"id_": "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be", "embedding": null, "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32129d5e-5441-400c-ad87-d3e6663675a3", "node_type": "1", "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "022083c345f5ca756af537ae6a5e1940a5efabc395bbac951cd84e012a8baf31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 242, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311": {"__data__": {"id_": "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eba3be5954eeb0a9311ef9836edd8e55818ac2f928105f8617c44917dbb062a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "dfa62d043018eabe2b73c0f5a741fd437ad6219af065d177bfeef0d158127e1c", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 365, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b": {"__data__": {"id_": "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "567718ce09a235516c59d83d30db3a76390f66370e7c6c7151d97a5564b810fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7847a9ae-ae82-449d-b4a2-d16ca3f7983b", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "ed68e8fd717353b7f09af06aefbedf950b43b4b04274a32f1c1af039221032fd", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 435, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7847a9ae-ae82-449d-b4a2-d16ca3f7983b": {"__data__": {"id_": "7847a9ae-ae82-449d-b4a2-d16ca3f7983b", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "378fc31caabd87397d9cc15005ec5b0d7994b4d99a770ac27b81220cc5b5cba9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "9a454d927d283df3dc83ccf67644b7a7f0ec8bf8aa324c1cabd994e1b5c5e34e", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 605, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58": {"__data__": {"id_": "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7847a9ae-ae82-449d-b4a2-d16ca3f7983b", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "262ee59ae985b01c362d9a9abc1fd969d7e9b4a7327d9a5391057fde37c30de6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20bfb039-f257-4d6c-817e-48b47fe7f7e3", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "original_text": "From Canada, dial +1 (855) 669-9658. "}, "hash": "1b213a7756c424ecf3addb9bb48353d2152023acac14aeb291821951915638c7", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 747, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20bfb039-f257-4d6c-817e-48b47fe7f7e3": {"__data__": {"id_": "20bfb039-f257-4d6c-817e-48b47fe7f7e3", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43ce278a4fa0e5291b6a3d6c9733c40d807b3a966157dce0be3abcb597391ab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. "}, "hash": "3b4f5a521c2e71351b97fc4a6cd7761df5761452f46560c0cee60aa15a813e7b", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial +1 (855) 669-9658. ", "start_char_idx": 821, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c": {"__data__": {"id_": "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20bfb039-f257-4d6c-817e-48b47fe7f7e3", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c2691c11ba1414e4547efbcb611d3d2323d64bd38b4eadad7f5b287f23201a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa50dc57-e016-4485-801a-d123966977b2", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "The access code for the replay is 10150879.\n"}, "hash": "3e29a202e1518a13cded6073f41dde79bc70208769eef004dfebacf8f7e58a15", "class_name": "RelatedNodeInfo"}}, "text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "start_char_idx": 858, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa50dc57-e016-4485-801a-d123966977b2": {"__data__": {"id_": "aa50dc57-e016-4485-801a-d123966977b2", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "The access code for the replay is 10150879.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daf4dd39de7c6a771f9fe1c61f9469ab1833101b770cd7e34fcda68e2deff717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6cec582-1c3f-4367-b6a6-014661776111", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n"}, "hash": "b1deebdfbf3756f196ef580bf31954e96bb75e7371efb01340a989eae1293986", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10150879.\n", "start_char_idx": 925, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6cec582-1c3f-4367-b6a6-014661776111": {"__data__": {"id_": "a6cec582-1c3f-4367-b6a6-014661776111", "embedding": null, "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa50dc57-e016-4485-801a-d123966977b2", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "The access code for the replay is 10150879.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb84a0fb7df99cb6442b995d7bfbf70927991ed1d103e1ea36d652d38b271806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "fed887c1d07a89c32d6a8ecf77823f8368103383c6999ccedeae6522254ea7ea", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "start_char_idx": 969, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf": {"__data__": {"id_": "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf", "embedding": null, "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6cec582-1c3f-4367-b6a6-014661776111", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7565ed7c894a08198993a73049509d74b1bcd136490300f5e520bf2742384729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7", "node_type": "1", "metadata": {"window": "The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "d396e213bbcf016e7f08eeb9013ee4b03a8918cef7789e04f02417e441cd4889", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1178, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7": {"__data__": {"id_": "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7", "embedding": null, "metadata": {"window": "The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d18590d48cf96d8009a3b71514fdba0704cc5d4416c0a75f96991a9837ea1e51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e480971d-b011-4a97-8220-8e7c7f83c5d8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "f7ca8460e3ea3074a702b3dee34d46429ad6763aedb5c57c1ad50389cfbca5ca", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 1307, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e480971d-b011-4a97-8220-8e7c7f83c5d8": {"__data__": {"id_": "e480971d-b011-4a97-8220-8e7c7f83c5d8", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7", "node_type": "1", "metadata": {"window": "The access code for the replay is 10150879.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd70e82c452a2f0fb905ef41703db355c7e5c9d7f64fd896ea4fc6eb94e6e964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca0babba-9681-448c-80d6-9472b1448f81", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "fe6eaba1737c4c83273e0bc85d85b509502a306834a842c211b6730a4b76847b", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 1520, "end_char_idx": 1755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca0babba-9681-448c-80d6-9472b1448f81": {"__data__": {"id_": "ca0babba-9681-448c-80d6-9472b1448f81", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e480971d-b011-4a97-8220-8e7c7f83c5d8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nCredit Suisse 2021 London Global Healthcare Conference March 2-4, 2021.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d00da3fb88188977477ea9bf2f92bc1397731b1d68b4972014d09b182dc94ee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aeec7bc-adaf-4b5f-bad0-f53d95416544", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. "}, "hash": "e064325267baa8c0c501a138d48353bf7e69218c95e0f6890214a335d7ea8ea1", "class_name": "RelatedNodeInfo"}}, "text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 1755, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aeec7bc-adaf-4b5f-bad0-f53d95416544": {"__data__": {"id_": "3aeec7bc-adaf-4b5f-bad0-f53d95416544", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca0babba-9681-448c-80d6-9472b1448f81", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73302fc9b5705169c08dc0a761173df7b7792128fb828ad03b113e3b39d0cecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea93543-d1fa-46e7-bd9e-6159ce6e27be", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "12c7abe705d813f4dd41dff4b40eef2d1db63480b46b070c22b2aaeffce0c50e", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "start_char_idx": 1870, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea93543-d1fa-46e7-bd9e-6159ce6e27be": {"__data__": {"id_": "6ea93543-d1fa-46e7-bd9e-6159ce6e27be", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aeec7bc-adaf-4b5f-bad0-f53d95416544", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b627721db54eec8483e87b062a912d4e57c52ac2eaa9cd34d83470928497827a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d69f50b4-c207-4c43-903e-9acd02e9c392", "node_type": "1", "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. "}, "hash": "c445d6f084b5924c80fa917f28bff13037da22a312fa0703d66acce5f334836e", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 1968, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d69f50b4-c207-4c43-903e-9acd02e9c392": {"__data__": {"id_": "d69f50b4-c207-4c43-903e-9acd02e9c392", "embedding": null, "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea93543-d1fa-46e7-bd9e-6159ce6e27be", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c913fed272dee98f995fb8e55a38e4e2ad1dc882268b5d47d7b09190aa85114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4408110-3196-40bd-8b09-6cd9012762e1", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. "}, "hash": "5c9dc2103624e4acc625232cc8005f5c3bbb252dee9ffe5c5a348431c2ae05af", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "start_char_idx": 2015, "end_char_idx": 2305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4408110-3196-40bd-8b09-6cd9012762e1": {"__data__": {"id_": "a4408110-3196-40bd-8b09-6cd9012762e1", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d69f50b4-c207-4c43-903e-9acd02e9c392", "node_type": "1", "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a53ea747ee102acb8f88c990cbf59e03ddb1c1134986744e84e205ec1e463262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bcfdd72-e566-43bc-ba00-88f6d1a24064", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. "}, "hash": "f92a2242eb896223a2b9654ddcd84e8e0207ab7718aa29d387a15bf97ac5e39a", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "start_char_idx": 2305, "end_char_idx": 2655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bcfdd72-e566-43bc-ba00-88f6d1a24064": {"__data__": {"id_": "9bcfdd72-e566-43bc-ba00-88f6d1a24064", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4408110-3196-40bd-8b09-6cd9012762e1", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "058b9f10832a39b6032445030c47f8a1342fe581682676b4ad68e9f526826925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70091946-07df-4e1b-ae40-550f67a0b2e9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. "}, "hash": "2d022cbe79641b733c65310983b44c955b05a750cf2b24325321949dd105cb4a", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "start_char_idx": 2655, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70091946-07df-4e1b-ae40-550f67a0b2e9": {"__data__": {"id_": "70091946-07df-4e1b-ae40-550f67a0b2e9", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bcfdd72-e566-43bc-ba00-88f6d1a24064", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebedb5179126565bcf49b0b12b82c99857e74809c5342155b30d975813d43580", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e165a69c-36b1-41a8-af08-661e0ddb4ce2", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5"}, "hash": "44506cc34c6cccd01aaba075c651f3d346e27dc96c5622a7133fa41987626b85", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 2817, "end_char_idx": 3016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e165a69c-36b1-41a8-af08-661e0ddb4ce2": {"__data__": {"id_": "e165a69c-36b1-41a8-af08-661e0ddb4ce2", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4dbf1638d803b8d74eb85f746b83bf933577485f34cb0f332b56e93949a43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70091946-07df-4e1b-ae40-550f67a0b2e9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e37bb0ea8a3e9175251a66267f063760e1d2c9eff5c13c1833e95abef0577235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f9fb7af-9747-4709-b93d-5341bd64c0a9", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "f55b3a1506bbb37191e48fd58767f9677a853160cb3782be462a2388ea14c7f8", "class_name": "RelatedNodeInfo"}}, "text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "start_char_idx": 3016, "end_char_idx": 5482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f9fb7af-9747-4709-b93d-5341bd64c0a9": {"__data__": {"id_": "1f9fb7af-9747-4709-b93d-5341bd64c0a9", "embedding": null, "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e165a69c-36b1-41a8-af08-661e0ddb4ce2", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives\nto detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution\nor suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled\nsubstances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court\nlitigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui\ntam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of\npharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement;\nmaterial adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less\nfavorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or\nsupplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company\u2019s ability to consummate\nthe proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s Alliance Healthcare businesses and related strategic transactions; the\nregulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms\nexpected or on the anticipated schedule or at all; the integration of the Alliance Healthcare business into the Company being more\ndifficult, time consuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted\n5", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48df22284de4c868fb8a2d7882e93de9b4afc30b9eecbadee1961ab69a8d4377", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed99e983-27cb-4134-b209-c20d8867fdce", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S. "}, "hash": "f61e4cb85463936eb79708c1e981e476bebefcdbc16d28e7d944a18fdd5f1420", "class_name": "RelatedNodeInfo"}}, "text": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed99e983-27cb-4134-b209-c20d8867fdce": {"__data__": {"id_": "ed99e983-27cb-4134-b209-c20d8867fdce", "embedding": null, "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f9fb7af-9747-4709-b93d-5341bd64c0a9", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e7340c497b956950b14da078d2f5f78436137211c1efa2936009a56794e478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c353602a-d05a-4da8-8802-4cb019f258bc", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. "}, "hash": "b50f95b59165512d8ab5e41da0b8f7409e6e24451112ebaa99108ca358f123a4", "class_name": "RelatedNodeInfo"}}, "text": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S. ", "start_char_idx": 915, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c353602a-d05a-4da8-8802-4cb019f258bc": {"__data__": {"id_": "c353602a-d05a-4da8-8802-4cb019f258bc", "embedding": null, "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed99e983-27cb-4134-b209-c20d8867fdce", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11977d2e77efc1c8b2cdaa2e9a5820a709dc0c78f2da7e9398c6f6d618e6cc72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7af88a5-8758-4465-8187-7b96ffa71bc1", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. "}, "hash": "02400c64a8ca93708ebe7ed2b3582b341e2524751ce98b04b394757446634e81", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "start_char_idx": 1126, "end_char_idx": 2751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7af88a5-8758-4465-8187-7b96ffa71bc1": {"__data__": {"id_": "a7af88a5-8758-4465-8187-7b96ffa71bc1", "embedding": null, "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c353602a-d05a-4da8-8802-4cb019f258bc", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d246a2b7b5cc4c4d647e966774509b7d0165fb2621d83ad22accae81c4da329", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfed1781-bd80-4dfd-bd41-9b05a3718727", "node_type": "1", "metadata": {"window": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n"}, "hash": "57e3388d674e1d18fd5e610d138210e538ace9d3edee96e9f2af746e5b41085e", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "start_char_idx": 2751, "end_char_idx": 3166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfed1781-bd80-4dfd-bd41-9b05a3718727": {"__data__": {"id_": "bfed1781-bd80-4dfd-bd41-9b05a3718727", "embedding": null, "metadata": {"window": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7af88a5-8758-4465-8187-7b96ffa71bc1", "node_type": "1", "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc9daf02a5def31726249bce5e44a6e4638b2ecf6cde5b305f8f6a65f2721e30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a8428db-e65a-49bb-8bcb-1b0093c86637", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6"}, "hash": "3c9cbc660afad51109a228e247678a766371132780f4d1e31ed63df0cbcca2b2", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "start_char_idx": 3166, "end_char_idx": 3315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a8428db-e65a-49bb-8bcb-1b0093c86637": {"__data__": {"id_": "4a8428db-e65a-49bb-8bcb-1b0093c86637", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "84eac33e-a33c-4491-92d8-95e95fe53864", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f12aadaa765489f2698c39e0ad2eed5c5be4b7334f6007cf12e131a6857cff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfed1781-bd80-4dfd-bd41-9b05a3718727", "node_type": "1", "metadata": {"window": "and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec1dc466806141f42613f01c4dd857803a0913c9dad027f120c4ea4f92b21196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf42674f-7fcc-4894-bd3b-f40409f5684f", "node_type": "1", "metadata": {"window": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "original_text": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7"}, "hash": "c32e72be681a92e564d263b970cf9a8153939d5c9907229b1a55d6134628e19c", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "start_char_idx": 3315, "end_char_idx": 3953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf42674f-7fcc-4894-bd3b-f40409f5684f": {"__data__": {"id_": "bf42674f-7fcc-4894-bd3b-f40409f5684f", "embedding": null, "metadata": {"window": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "original_text": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fc7aef28-971c-436a-be01-5362f39dd466", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9e40fd0247a42c16483a4d34587b779498fa415209d6f3187b244b4a7bd66be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a8428db-e65a-49bb-8bcb-1b0093c86637", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0\u00a0 \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a09.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a051,064,326 \u00a0\u00a0\u00a0\u00a0 \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a09.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,452,230 \u00a0\u00a0\u00a02.77 %\u00a01,231,214 \u00a0\u00a02.57 %\u00a018.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0735,068 \u00a0\u00a0\u00a01.40 %\u00a0685,953 \u00a0\u00a01.43 %\u00a07.2 %\nDepreciation and amortization \u00a099,553 \u00a0\u00a0\u00a00.19 %\u00a0104,515 \u00a0\u00a00.22 %\u00a0(4.7 )%\n6", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e166c9bd482b2b829da0769a85a71cdaa5e729ffb81f6d21d837552b0419d76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a63e6680-ccce-4a5b-8dae-c8f387a1bddb", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "original_text": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020. "}, "hash": "3e3cf7edf1e4c1b8f7e05749d24767fd85fde1ad92f3edf32baf0b4850af47ab", "class_name": "RelatedNodeInfo"}}, "text": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "start_char_idx": 0, "end_char_idx": 1142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a63e6680-ccce-4a5b-8dae-c8f387a1bddb": {"__data__": {"id_": "a63e6680-ccce-4a5b-8dae-c8f387a1bddb", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "original_text": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020. ", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf42674f-7fcc-4894-bd3b-f40409f5684f", "node_type": "1", "metadata": {"window": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "original_text": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f962aceac165634d0bbd4625d42c918f7e95d131bbd1634514d30f6a85c996d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "original_text": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n"}, "hash": "f43ac32ed93caa90a2ac6212b09acc63d06d9aaf877cca16b91d764f16b66f8a", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020. ", "start_char_idx": 0, "end_char_idx": 125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8": {"__data__": {"id_": "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "original_text": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a63e6680-ccce-4a5b-8dae-c8f387a1bddb", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "original_text": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020. ", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d326abc817c0403c96119f5ef3391e5b22c40b724c219ee5a400b1c0b3ed3767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daa67c4e-9122-4a5c-a37c-500f10fa8ccb", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "original_text": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020. "}, "hash": "71a8fc8253da21d10663465802251579ebc76c3b15141fb1412476a0a025c578", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n", "start_char_idx": 125, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daa67c4e-9122-4a5c-a37c-500f10fa8ccb": {"__data__": {"id_": "daa67c4e-9122-4a5c-a37c-500f10fa8ccb", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "original_text": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020. ", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "original_text": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8c627c3c2569e37bbe51024a622c33653667cc1b54e0ee2b4646ad03885beb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e025f58a-f885-4d76-b95f-f50a1ebc1d3f", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n"}, "hash": "b672c207d7cb0274e2b3d00bf69c4bbaefca032c7272965567d9f9504cd87fbe", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020. ", "start_char_idx": 318, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e025f58a-f885-4d76-b95f-f50a1ebc1d3f": {"__data__": {"id_": "e025f58a-f885-4d76-b95f-f50a1ebc1d3f", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daa67c4e-9122-4a5c-a37c-500f10fa8ccb", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "original_text": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020. ", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf63d1ca992536e0f049fa4367c7bffb07fafec49a69f23d95f9ae284c6ffcef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe54f4e-acfb-4093-80ec-67f9f21e6eac", "node_type": "1", "metadata": {"window": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n"}, "hash": "15ee46f5463abec21a9359182fa992b86ce7f09e16ec76e7a8b3ed194e879887", "class_name": "RelatedNodeInfo"}}, "text": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "start_char_idx": 668, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbe54f4e-acfb-4093-80ec-67f9f21e6eac": {"__data__": {"id_": "bbe54f4e-acfb-4093-80ec-67f9f21e6eac", "embedding": null, "metadata": {"window": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e025f58a-f885-4d76-b95f-f50a1ebc1d3f", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2323db4785b18c8372c2b9211fb7e298c4b44505380631240a4bcba9ce3db2ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a6226f-273f-4013-b375-9a3c4dcb88b4", "node_type": "1", "metadata": {"window": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n"}, "hash": "1f7b8de67f022dd81fd4d899072953d6aa5e326f89e8ed15cf43e1d81ee30b7b", "class_name": "RelatedNodeInfo"}}, "text": "3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "start_char_idx": 1057, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a6226f-273f-4013-b375-9a3c4dcb88b4": {"__data__": {"id_": "e2a6226f-273f-4013-b375-9a3c4dcb88b4", "embedding": null, "metadata": {"window": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbe54f4e-acfb-4093-80ec-67f9f21e6eac", "node_type": "1", "metadata": {"window": "Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07a754fe2c1ffb1ff31fa1f3870619b6accd87910cf5fe705d250c9390f1a376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19af3282-8035-4007-9576-d25c930021c9", "node_type": "1", "metadata": {"window": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8"}, "hash": "ac8f0c02e5948008e7f83a70416bd5e5665780d7952ac16df585cc18484d0bdc", "class_name": "RelatedNodeInfo"}}, "text": "4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "start_char_idx": 1220, "end_char_idx": 1480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19af3282-8035-4007-9576-d25c930021c9": {"__data__": {"id_": "19af3282-8035-4007-9576-d25c930021c9", "embedding": null, "metadata": {"window": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e890ed33-efcd-4274-8eac-0080349b36c1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d27c4819be5ab531fdf7da7e9455cd7191a17705d88227617cb46c6a5ad938b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2a6226f-273f-4013-b375-9a3c4dcb88b4", "node_type": "1", "metadata": {"window": "2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7594552572034ff1104ea05f8312619f8df7ae5511288873185bc4ce0ceef325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2822c04b-080f-4470-9eb3-f0395d7a9b8f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "646925da6e668f16a1edae8c66e148c804e853a4553f9fe2321aaf33a56c6340", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "start_char_idx": 1480, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2822c04b-080f-4470-9eb3-f0395d7a9b8f": {"__data__": {"id_": "2822c04b-080f-4470-9eb3-f0395d7a9b8f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3e3e2e84823c7f071703416b86fd80e1a2b951a7c95b99aacc21e40ee23c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19af3282-8035-4007-9576-d25c930021c9", "node_type": "1", "metadata": {"window": "Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n 3\u00a0Includes a $14.0 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended December 31, 2020.\n 4\u00a0Includes $52.3 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the shutdown of the PharMEDium business in the three months ended December 31,\n2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax \nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,452,230 \u00a0\u00a0$905,002 \u00a0\u00a0$547,228 \u00a0\u00a0$527,882 \u00a0\u00a0$149,175 \u00a0\u00a0$(3,862 )\u00a0$374,845 \u00a0\u00a0$1.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(25,727 )\u00a0\u2014 \u00a0\u00a0(25,727 )\u00a0(25,727 )\u00a0(4,976 )\u00a0\u2014 \u00a0\u00a0(20,751 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,034 )\u00a025,034 \u00a0\u00a025,034 \u00a0\u00a04,096 \u00a0\u00a0(437 )\u00a020,501 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(70,381 )\u00a070,381 \u00a0\u00a070,381 \u00a0\u00a011,974 \u00a0\u00a0\u2014 \u00a0\u00a058,407 \u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n8", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c65f31d8f24fcd8b43b25168f39aad5f8dc48c41c93d624f7562070edba88dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n"}, "hash": "61fe2d7be107cc67212ef89b081f73ae73fdc5029f26feaca8e40882bcc3cb0a", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2": {"__data__": {"id_": "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3e3e2e84823c7f071703416b86fd80e1a2b951a7c95b99aacc21e40ee23c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2822c04b-080f-4470-9eb3-f0395d7a9b8f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e085ff4154433943b570d126942bb616c74c924125412781cd21291559bd5b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0"}, "hash": "584d96fce5a7bda64a22ddb66e2900ae597ccfbb5dadf527310c6e4d928b768f", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n", "start_char_idx": 287, "end_char_idx": 695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f": {"__data__": {"id_": "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3e3e2e84823c7f071703416b86fd80e1a2b951a7c95b99aacc21e40ee23c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd33ce6773110d1b303c1ab6a03f75528617f3b1a657c3c671381d2193ca5413", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c514b4d-8591-4437-855f-b64c3acadc2a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c50d4d1c50386add675da978a9145b38503e63465890735977cb21117eee353f", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0", "start_char_idx": 695, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c514b4d-8591-4437-855f-b64c3acadc2a": {"__data__": {"id_": "7c514b4d-8591-4437-855f-b64c3acadc2a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3e3e2e84823c7f071703416b86fd80e1a2b951a7c95b99aacc21e40ee23c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c584b8688a1f2bdfe1086b73c3ff01e66a3f43d2078667898574f5b8f9bfe5a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f39011c-4fd3-48dc-b849-e05cfdf7b170", "node_type": "1", "metadata": {"window": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9"}, "hash": "a79f50ecce21134281aac39694492e4c57815af840661eda8fbdad324834c998", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 871, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f39011c-4fd3-48dc-b849-e05cfdf7b170": {"__data__": {"id_": "3f39011c-4fd3-48dc-b849-e05cfdf7b170", "embedding": null, "metadata": {"window": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3e3e2e84823c7f071703416b86fd80e1a2b951a7c95b99aacc21e40ee23c1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c514b4d-8591-4437-855f-b64c3acadc2a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dae897c2eb6fbc8f6a89dce4915d0168a27b793a3b9050ca24dc7f3727af586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "746b0dcd-4cf3-46a5-a942-05df0ebc517c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10"}, "hash": "f84d3c6f5cccbfb60f184c15fb9e72026855a3ff5569c863c619770208a773f9", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "start_char_idx": 1048, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "746b0dcd-4cf3-46a5-a942-05df0ebc517c": {"__data__": {"id_": "746b0dcd-4cf3-46a5-a942-05df0ebc517c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "page_label": "10", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eec2445c-cf61-4e0c-a8f6-0696315e2372", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6db74636b5715669d0ed1e9b46bc4c1e90d0a17ac48e3591f3ac411559c522d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f39011c-4fd3-48dc-b849-e05cfdf7b170", "node_type": "1", "metadata": {"window": "prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\nOperating OperatingIncome\nBefor e\nIncomeIncome\nTaxNet Loss\nAttributable t o\nNoncontr ollingNet Income\nAttributableDilut ed\nEarnings\nPer\n9", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dca07192c8421b6e7a47701ab1c3b80ff61aff2b9248e27644cfd4abbb53998f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb8bbc7-5258-486a-bae8-040bcb738fa7", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "be6d8eeb723edb60b11933731ba3338c13e7cfb3f6080fdd80dff9c069dd7155", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "start_char_idx": 0, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb8bbc7-5258-486a-bae8-040bcb738fa7": {"__data__": {"id_": "1cb8bbc7-5258-486a-bae8-040bcb738fa7", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f62ec19-fd05-455f-addb-ba03898826c4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca0fc71e3b4e9ea88e9d61180f5e66e74d3ef2de8ba899274ca67e4c0677bf4a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "746b0dcd-4cf3-46a5-a942-05df0ebc517c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "page_label": "10", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "686fa5b588cbee821303b95f69546bd1818df19cecdff3a4acedb75e7534d4df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3a9dcd-544b-42fa-8436-60d4a50fdccb", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11"}, "hash": "092414eb976fedf457cd66c80e95cb9b974e80e4ffd836867784c6b012e18711", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3a9dcd-544b-42fa-8436-60d4a50fdccb": {"__data__": {"id_": "ee3a9dcd-544b-42fa-8436-60d4a50fdccb", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f62ec19-fd05-455f-addb-ba03898826c4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca0fc71e3b4e9ea88e9d61180f5e66e74d3ef2de8ba899274ca67e4c0677bf4a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb8bbc7-5258-486a-bae8-040bcb738fa7", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9daf84deec48a2d775b0eb9260a19e8cf245dea49a1dd0c1580d19363efc4483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0186fe30-ba76-4ed2-a63f-9ce90a282e03", "node_type": "1", "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "edfa3469540dc6c64e334eaf69ba4498b4c602aeb38bd8e721aded4911c6e3c3", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "start_char_idx": 219, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0186fe30-ba76-4ed2-a63f-9ce90a282e03": {"__data__": {"id_": "0186fe30-ba76-4ed2-a63f-9ce90a282e03", "embedding": null, "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "905f0978-1ca4-4ec8-b37d-9be865985c83", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "121cb81e04805ecdd6ab0cd7af852104a83c166cf0e06bb10f0377869520799b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3a9dcd-544b-42fa-8436-60d4a50fdccb", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "110b146d3192985fbee5069d3342ae9f5acbee101341e0bdf24235ba5bd640cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f22a854-b0b3-41ec-8742-fc1a908e36b3", "node_type": "1", "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12"}, "hash": "1430c3dac42fd6d4489efe6ccdc5e942cc582449eb501fabdeaaec8900d470f2", "class_name": "RelatedNodeInfo"}}, "text": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f22a854-b0b3-41ec-8742-fc1a908e36b3": {"__data__": {"id_": "2f22a854-b0b3-41ec-8742-fc1a908e36b3", "embedding": null, "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12", "page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "905f0978-1ca4-4ec8-b37d-9be865985c83", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "121cb81e04805ecdd6ab0cd7af852104a83c166cf0e06bb10f0377869520799b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0186fe30-ba76-4ed2-a63f-9ce90a282e03", "node_type": "1", "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f228b3f55e785ea992c7e1b617c7cb9142a8a062c4e08fe3234c98a4fed0df9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a86f974c-1137-45d1-a550-b5984c307bbf", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13"}, "hash": "691e19f407590dba3a1835dc8d614d1566cb4044d105af13044f85d47e933518", "class_name": "RelatedNodeInfo"}}, "text": "12", "start_char_idx": 383, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a86f974c-1137-45d1-a550-b5984c307bbf": {"__data__": {"id_": "a86f974c-1137-45d1-a550-b5984c307bbf", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c2f3d50-6806-4b33-9c9e-674d04e0c4e9", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed2150d6b24d1c9c8ebd0cb906fabaf859df203b4c25cf5db8781fc762d04616", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f22a854-b0b3-41ec-8742-fc1a908e36b3", "node_type": "1", "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12", "page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b80e3c733d21d6c577c78855a14b770ca04443e38cc3661d1e406d7fb87b289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2", "node_type": "1", "metadata": {"window": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "original_text": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14"}, "hash": "414dfd4dbc8bfa25fdd478e86042ca9f9c289cb99512ab5acfa1b9dac61399e0", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "start_char_idx": 0, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2": {"__data__": {"id_": "f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2", "embedding": null, "metadata": {"window": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "original_text": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc8e7659-908c-4294-9764-5ea7ec58ac51", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c37e93d152ad0f22e110d626a6c906c0c1c8fd6ab21eb69e0ef13604dea0d74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a86f974c-1137-45d1-a550-b5984c307bbf", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce1c3583bb6bab960cbe2e2e4aab627f6cc41cefbb4909ac07d6cb64bc849285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6815612f-ae64-4430-83f4-fb5986dff386", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n"}, "hash": "cafb44dced435341300d7613217d411171a9e6f0536248c59577ef0ee0b9e904", "class_name": "RelatedNodeInfo"}}, "text": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "start_char_idx": 0, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6815612f-ae64-4430-83f4-fb5986dff386": {"__data__": {"id_": "6815612f-ae64-4430-83f4-fb5986dff386", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2", "node_type": "1", "metadata": {"window": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "original_text": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4f2d64c486100b5e348355488c6097089622d12ade06065648620877c5e4817", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c1b1223-6b4c-4773-adf2-533bf8f8b890", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021. "}, "hash": "6e5fe378744f04c01be92f9fa0272a9d2bffffe4583b325808276e0b6c3c2e9f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n", "start_char_idx": 0, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c1b1223-6b4c-4773-adf2-533bf8f8b890": {"__data__": {"id_": "5c1b1223-6b4c-4773-adf2-533bf8f8b890", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6815612f-ae64-4430-83f4-fb5986dff386", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7e12f812b86fa7e675475f11b6cc836d171fe5396cfe50084fb072de6709c2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf9c1c70-c9ed-4a92-8759-25342e2b7646", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n"}, "hash": "f34be03133d53fc4708f041b9179c89e5aebe9af7fa5293110b08f90af0665df", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021. ", "start_char_idx": 859, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf9c1c70-c9ed-4a92-8759-25342e2b7646": {"__data__": {"id_": "cf9c1c70-c9ed-4a92-8759-25342e2b7646", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c1b1223-6b4c-4773-adf2-533bf8f8b890", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5e27f030b04b5b806b516a6405843c7b4e1e081cff014bf443a959fed9729fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb46ada3-e5a6-423c-9d44-5355478b35de", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "ce02b446f0b4dcbc84c6d7b9891b2814a2c22f1e7dceeb76379874adb985f5ab", "class_name": "RelatedNodeInfo"}}, "text": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n", "start_char_idx": 1015, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb46ada3-e5a6-423c-9d44-5355478b35de": {"__data__": {"id_": "cb46ada3-e5a6-423c-9d44-5355478b35de", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf9c1c70-c9ed-4a92-8759-25342e2b7646", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc2a86a3ca4a625203a65d844b2c893534f5ad0bf8d188d22c0f2e224bc77e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a061a161-e183-44aa-80b2-6d40d309cb23", "node_type": "1", "metadata": {"window": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "1bb81dca7733e9fa5889f53426d7db657ebd21813d7009c6abf92dc48675b050", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 1258, "end_char_idx": 1396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a061a161-e183-44aa-80b2-6d40d309cb23": {"__data__": {"id_": "a061a161-e183-44aa-80b2-6d40d309cb23", "embedding": null, "metadata": {"window": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb46ada3-e5a6-423c-9d44-5355478b35de", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c5b53c3270a624541fa6b760131151a9691b7d4b268a9001be105317df921d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d", "node_type": "1", "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "99588afea03317836ba51d70a552d0394a3cfb0ab19bf7aa5cbdbd1dac5b75ec", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1396, "end_char_idx": 1511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d": {"__data__": {"id_": "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d", "embedding": null, "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a061a161-e183-44aa-80b2-6d40d309cb23", "node_type": "1", "metadata": {"window": "2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ddb1556ff803cd8b3af31e92f64527c64a2cb7bd9554691b6dd3734b4a4cd97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e0b680-88bc-4940-9ef5-d81b34db8b38", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "These supplemental measures may vary from, and may\n15"}, "hash": "fc387f7b53a74e99f69750fc7bc84a06b6903d236fee83d560a495047893594b", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1511, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e0b680-88bc-4940-9ef5-d81b34db8b38": {"__data__": {"id_": "62e0b680-88bc-4940-9ef5-d81b34db8b38", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "These supplemental measures may vary from, and may\n15", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9fceb209dafdb79751efa8258831c0694a5c99d55d22eb44a97a3b1f4048b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d", "node_type": "1", "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4bf620602b0d8ed3661c1a0c964abadb83b3255388091e0944e1c88cc381d4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a34a9eb-058e-4aea-9e7b-e3e7638ead5b", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "not be comparable to, similarly titled measures by other companies.\n"}, "hash": "ba9c46b49cb627dc6da5e6fd1e5fc17f928e955005fd4cb6ad4ac3f10626685c", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\n15", "start_char_idx": 1651, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a34a9eb-058e-4aea-9e7b-e3e7638ead5b": {"__data__": {"id_": "0a34a9eb-058e-4aea-9e7b-e3e7638ead5b", "embedding": null, "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "not be comparable to, similarly titled measures by other companies.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e0b680-88bc-4940-9ef5-d81b34db8b38", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\n15", "original_text": "These supplemental measures may vary from, and may\n15", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a35c6cd81a682514095e2edcbc0273ce2ba836ea819cd1032bfab835d38ae7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8893fa00-3af8-42e7-85b6-30bfaa87a7c6", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "f783bafa345c0b751ad2435f483bb340ebcfe39d337726476bd7d5548a1a3503", "class_name": "RelatedNodeInfo"}}, "text": "not be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 0, "end_char_idx": 68, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8893fa00-3af8-42e7-85b6-30bfaa87a7c6": {"__data__": {"id_": "8893fa00-3af8-42e7-85b6-30bfaa87a7c6", "embedding": null, "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a34a9eb-058e-4aea-9e7b-e3e7638ead5b", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "not be comparable to, similarly titled measures by other companies.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d48281dac723f3f25b04c468a0d41ded6349f8d05cbfe7b16333080bab484f1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ff58101-ede1-444d-a9a5-dc233958d615", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "04a50e9e75df961da9fcc4dbbccf2a051248285108998a768b6fbcffa103fcee", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 68, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ff58101-ede1-444d-a9a5-dc233958d615": {"__data__": {"id_": "3ff58101-ede1-444d-a9a5-dc233958d615", "embedding": null, "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8893fa00-3af8-42e7-85b6-30bfaa87a7c6", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a3868d8671bc6d279f73aaa1eaee0d4b16ce9624b415fcd3dcbd8f2f16fefc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83c7e74d-0b9d-42d6-946f-80396d8cf8f5", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "2d85dbb42d74cb1fb3f326ea5ecdb5a3c4c4d625e896b7e2d6a2de464720c577", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 287, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83c7e74d-0b9d-42d6-946f-80396d8cf8f5": {"__data__": {"id_": "83c7e74d-0b9d-42d6-946f-80396d8cf8f5", "embedding": null, "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ff58101-ede1-444d-a9a5-dc233958d615", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f56fd7378c74c5b80bd9833aa88f4e8d5e7a06001ab7040dbfb4c44023c76a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dadeb5da-8514-4d83-b336-cca43c918eba", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. "}, "hash": "a2b4bcef1df71b6d2e8b20bcd712bcc2cd3dbf4de5046b3a5c5f4b8f47e06630", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 469, "end_char_idx": 750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dadeb5da-8514-4d83-b336-cca43c918eba": {"__data__": {"id_": "dadeb5da-8514-4d83-b336-cca43c918eba", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83c7e74d-0b9d-42d6-946f-80396d8cf8f5", "node_type": "1", "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91a74d71f1c08f834130955531194772685c3b0c17fe8e63ee35f22198773768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec448e0e-572d-4f64-afaa-e70c12c282aa", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. "}, "hash": "ed09dd8136a2c2baea0dd701ba58f99f98493e9076eafed1c1fb8ce3b5579dd4", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "start_char_idx": 750, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec448e0e-572d-4f64-afaa-e70c12c282aa": {"__data__": {"id_": "ec448e0e-572d-4f64-afaa-e70c12c282aa", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dadeb5da-8514-4d83-b336-cca43c918eba", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5aef93860be3a7c7e3b17118e5d078e794477bdfef158ae9356cc4469d0a97c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n"}, "hash": "6d917d4304398a3ed14cc1211d2e025ecd6ce0ef1068a3337ab636d44ac41855", "class_name": "RelatedNodeInfo"}}, "text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "start_char_idx": 1081, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3": {"__data__": {"id_": "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec448e0e-572d-4f64-afaa-e70c12c282aa", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12d4014177c2c34fe1809ec0e17cb220123822d43feefe75782df47c658209c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a75d4af2-4a48-4d61-b575-c4b00c8e3670", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. "}, "hash": "fdb2f5afc8fe096c0969080ce73ed0a917fa815cbbbfcd0e758ee554ec2d40a3", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "start_char_idx": 1247, "end_char_idx": 1330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a75d4af2-4a48-4d61-b575-c4b00c8e3670": {"__data__": {"id_": "a75d4af2-4a48-4d61-b575-c4b00c8e3670", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da53e11c805853c22e24997ef79e4acdcb691031c8941fb81e5b50ba4eec64d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5e810e9-b36a-428e-800c-4b6d1e809017", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "f2f904629433e10c06293f866f4baa4a1279d95adf9b0304056d2934d473b222", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 1330, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5e810e9-b36a-428e-800c-4b6d1e809017": {"__data__": {"id_": "c5e810e9-b36a-428e-800c-4b6d1e809017", "embedding": null, "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a75d4af2-4a48-4d61-b575-c4b00c8e3670", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium remediation costs.  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff4d9b3d651214c2d41322e42246ea0a8cd902f1c4a44d7ed5eacf9116a72e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "991a55fc-751a-4c88-a743-c100c0be8581", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown. ", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. "}, "hash": "f68b82739b30e8f347a90ae92c814e6a473ca33f630ff9c76825e20ee9a70bf3", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 1415, "end_char_idx": 1572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "991a55fc-751a-4c88-a743-c100c0be8581": {"__data__": {"id_": "991a55fc-751a-4c88-a743-c100c0be8581", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown. ", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5e810e9-b36a-428e-800c-4b6d1e809017", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "366b3b08981b278ab07c4d9e38115ad0132f2d6203d7aeca8a3eff24bc0d9bbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7ec767-b846-40f4-b379-ebac435a6bc1", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. "}, "hash": "9246713e0cca95561345b5c2bd2ea633d0944ede7be243a52ebfa442befeea02", "class_name": "RelatedNodeInfo"}}, "text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "start_char_idx": 1572, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7ec767-b846-40f4-b379-ebac435a6bc1": {"__data__": {"id_": "7f7ec767-b846-40f4-b379-ebac435a6bc1", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "991a55fc-751a-4c88-a743-c100c0be8581", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown. ", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed265604353d378cda6d886d7f308fa8bfc5929f463ab9fdf5544a53d48782a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "7391f5ec1fdb25e06f2fbd3b2e6c6127bce1c542a20b56c9d0bea815245c86ba", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "start_char_idx": 1872, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1": {"__data__": {"id_": "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7ec767-b846-40f4-b379-ebac435a6bc1", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "018b2cdbeef8fa92042f33fc5569e280099fc48559f39ecf8e17216b77b23a57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d1d27f1-3816-4b1a-a937-9af0cce13bb9", "node_type": "1", "metadata": {"window": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "The PharMEDium\nbusiness has since been permanently shutdown. "}, "hash": "05c9bbb2517c38a58005998509716486a984c815e29d82681852b59d7840600f", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 1996, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d1d27f1-3816-4b1a-a937-9af0cce13bb9": {"__data__": {"id_": "6d1d27f1-3816-4b1a-a937-9af0cce13bb9", "embedding": null, "metadata": {"window": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "The PharMEDium\nbusiness has since been permanently shutdown. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10ee073239ba75fbd820dc5e57645e783ea93558627e45648902a9feda5255a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6856b82-cd85-4e6c-84fb-167c8a794668", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n"}, "hash": "d903c6b3d18a823b7217a15a47d28ce247d1061c3e568a69eaa37f29f2071d31", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium\nbusiness has since been permanently shutdown. ", "start_char_idx": 2038, "end_char_idx": 2099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6856b82-cd85-4e6c-84fb-167c8a794668": {"__data__": {"id_": "e6856b82-cd85-4e6c-84fb-167c8a794668", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d1d27f1-3816-4b1a-a937-9af0cce13bb9", "node_type": "1", "metadata": {"window": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "The PharMEDium\nbusiness has since been permanently shutdown. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77815e5b71dbe2b8bb6ef5df7e60728a5616f63bc2782bae40a5607a3aa71f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6980210-6d86-4e4d-a93c-3f1ace73c07d", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. "}, "hash": "41157f7096abc741abd50876892f578998dd430534a466ffa422e609a66ff348", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "start_char_idx": 2099, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6980210-6d86-4e4d-a93c-3f1ace73c07d": {"__data__": {"id_": "f6980210-6d86-4e4d-a93c-3f1ace73c07d", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6856b82-cd85-4e6c-84fb-167c8a794668", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fade6287a2af7008be08cd788112d11dc2fac837cd356b914fbf0ef542634efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "425df418-507c-4cd9-8cdd-b83fcad6a616", "node_type": "1", "metadata": {"window": "The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. "}, "hash": "60b7dd201caec7a47dcdb6face841f463f4801b0f213bbc8cee492d80f229324", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "start_char_idx": 2281, "end_char_idx": 2586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "425df418-507c-4cd9-8cdd-b83fcad6a616": {"__data__": {"id_": "425df418-507c-4cd9-8cdd-b83fcad6a616", "embedding": null, "metadata": {"window": "The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6980210-6d86-4e4d-a93c-3f1ace73c07d", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d9e2f64ceb067fa27d25d8790daeb4aa87fa35f57682eabece6bdef91ea3e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c6e57bf-4883-4410-92f6-ad3113ab280b", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. "}, "hash": "8314c08ae3a9791a1d633529551b7072d7f6447620b6c356741baebbc4328d83", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "start_char_idx": 2586, "end_char_idx": 2682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c6e57bf-4883-4410-92f6-ad3113ab280b": {"__data__": {"id_": "8c6e57bf-4883-4410-92f6-ad3113ab280b", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "425df418-507c-4cd9-8cdd-b83fcad6a616", "node_type": "1", "metadata": {"window": "The PharMEDium\nbusiness has since been permanently shutdown.  LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d217a5a0bf0debc86190e0739a45757d9c87cb268993b339c57f1d94c85bf719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0d87a1d-ea02-46f5-a774-5338ea943afb", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. "}, "hash": "5413b0e2ed81f064c9dbe8ef3c601bdad181a5b2e1d29f1c3a65216e6654f985", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 2682, "end_char_idx": 2844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0d87a1d-ea02-46f5-a774-5338ea943afb": {"__data__": {"id_": "b0d87a1d-ea02-46f5-a774-5338ea943afb", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c6e57bf-4883-4410-92f6-ad3113ab280b", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities, product\nmix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffa54f97dc6d8ed3788322872f5b1c612c9f2a180c8ff42633d09a5fc0e8f91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be542bb2-4949-474b-a001-f20f55bce10f", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n"}, "hash": "7b78e71a48fb60bb5b607802af4d6035255a4f88334e603644be9afd25369151", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "start_char_idx": 2844, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be542bb2-4949-474b-a001-f20f55bce10f": {"__data__": {"id_": "be542bb2-4949-474b-a001-f20f55bce10f", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0d87a1d-ea02-46f5-a774-5338ea943afb", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of PharMEDium assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594c2c453ec936428cbd526e1d5801351c2e84d724d98b7d7f104c9916b212f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e1677e3-4e65-44d4-be26-2e51ada0077d", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "d87692fc0c125836e819f2462b2f4489b482e3fc9616bffb7bf80fc635b02a84", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "start_char_idx": 2956, "end_char_idx": 3289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e1677e3-4e65-44d4-be26-2e51ada0077d": {"__data__": {"id_": "9e1677e3-4e65-44d4-be26-2e51ada0077d", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be542bb2-4949-474b-a001-f20f55bce10f", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd7e8f9d9ecc26942e858067776932e80ca71f2da93099005445a61bd5f0b5fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8615859-1b92-4f9f-b4c2-b2525cac831e", "node_type": "1", "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "469856772f8bdb75bea5dd96cd14094c53127dc8a9e931ae6ec0870c5807d649", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3289, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8615859-1b92-4f9f-b4c2-b2525cac831e": {"__data__": {"id_": "b8615859-1b92-4f9f-b4c2-b2525cac831e", "embedding": null, "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e1677e3-4e65-44d4-be26-2e51ada0077d", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdf9274c2369e24a0a60da04e1fff820ebb069ce337218faa789d69813ae720e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e42a445b-bb21-4e87-862f-efefeb9aa399", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "67b18b241b03bdd713265274c88e0dc95e5b7d717751d552ad87da34307e903c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3538, "end_char_idx": 3631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e42a445b-bb21-4e87-862f-efefeb9aa399": {"__data__": {"id_": "e42a445b-bb21-4e87-862f-efefeb9aa399", "embedding": null, "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8615859-1b92-4f9f-b4c2-b2525cac831e", "node_type": "1", "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5adf4ab9786db90d872d234e5b55bfd082ab4e75acc18376af5b29dc90eb896d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d186b80-cde7-4802-a1df-d352a9d47bef", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "0d9b97be19240a91b7c2ba03d222d59831e6b40f1429a6e9a394cb0770d68e92", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3631, "end_char_idx": 3878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d186b80-cde7-4802-a1df-d352a9d47bef": {"__data__": {"id_": "9d186b80-cde7-4802-a1df-d352a9d47bef", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e42a445b-bb21-4e87-862f-efefeb9aa399", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of PharMEDium assets, that\nare unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate\nthe analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c4ac53fe82d1d393ada03c02f3a9295ac00a035956cc9c8ca1bf0fd99e1d999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "677c71d0-f3a7-41bc-b088-74c61af5243e", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. "}, "hash": "361bf324dc1371c6f51441ccf5b82f9288a534f7dee5479159c8b6ff219d957a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3878, "end_char_idx": 4083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "677c71d0-f3a7-41bc-b088-74c61af5243e": {"__data__": {"id_": "677c71d0-f3a7-41bc-b088-74c61af5243e", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d186b80-cde7-4802-a1df-d352a9d47bef", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a87cd9ffb5200a6627918384b6e7034ec78773ff5f91e02918cb5a0fa52b101f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ee12c98-a69c-4fca-990f-d3e1124df261", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n"}, "hash": "db1ac1b6f128017bcedbec082a3cbe30b8022dae32aca7940373e48cd9f743f6", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "start_char_idx": 4083, "end_char_idx": 4344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee12c98-a69c-4fca-990f-d3e1124df261": {"__data__": {"id_": "3ee12c98-a69c-4fca-990f-d3e1124df261", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "677c71d0-f3a7-41bc-b088-74c61af5243e", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af1ae662e681ba030f6e5f32b5003a8a88ecbb1ce53bb46397541d2b3f57ca9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ed7bc3a-f046-496d-b8e4-892b60951963", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "a2a1c328afd4c190f8ab2da590c47b22d687baeca123db49a7a6de0e72ac9bf6", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "start_char_idx": 4344, "end_char_idx": 4509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ed7bc3a-f046-496d-b8e4-892b60951963": {"__data__": {"id_": "7ed7bc3a-f046-496d-b8e4-892b60951963", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ee12c98-a69c-4fca-990f-d3e1124df261", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f32b8a42071f5a3f0a9db6970ee437afcf8f7adbc1a715f2d67cc87311af853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "676181bd-cda9-42e7-a030-6d29a57569ca", "node_type": "1", "metadata": {"window": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "f6f4cc36a004969933b548037ed60a1aa9fa2ccf45274e5dd495be9ae9e973b5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 4509, "end_char_idx": 4706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "676181bd-cda9-42e7-a030-6d29a57569ca": {"__data__": {"id_": "676181bd-cda9-42e7-a030-6d29a57569ca", "embedding": null, "metadata": {"window": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ed7bc3a-f046-496d-b8e4-892b60951963", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "786051eacde3fa80dccbc86a678aea2f75a1bd3bfa277f62cb56874d44a3a72f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69e69e26-3fe1-4489-b6a6-e1c34513b742", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "e80f2607352a3612aacf5887177efd43dc65a8932a172200de18c515cb1e6f94", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 4706, "end_char_idx": 4978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69e69e26-3fe1-4489-b6a6-e1c34513b742": {"__data__": {"id_": "69e69e26-3fe1-4489-b6a6-e1c34513b742", "embedding": null, "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "676181bd-cda9-42e7-a030-6d29a57569ca", "node_type": "1", "metadata": {"window": "In addition, the gain on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three months ended December 31, 2020 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ca57f43ab1f598d4690297e85dc6317d88416ba3b578d13da5edbab6a915496", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef70dfe5-9037-40cd-9e61-b01d9d748c55", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. "}, "hash": "3204aad3ad965f4aa1db239eb48304dafa14a154536043f0df6db6a4ee98033a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4978, "end_char_idx": 5216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef70dfe5-9037-40cd-9e61-b01d9d748c55": {"__data__": {"id_": "ef70dfe5-9037-40cd-9e61-b01d9d748c55", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69e69e26-3fe1-4489-b6a6-e1c34513b742", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caeac0c73c20c0bdfbff6275ff676c0fbf86596414a1360e4c8c3bec27e59c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b290d85b-1104-443f-894d-0aea6aa5e45e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16"}, "hash": "2b9becbad8982df767a6478a6767a2b2c6cd089f4ec7f82d1f99536681d731cf", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "start_char_idx": 5216, "end_char_idx": 5544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b290d85b-1104-443f-894d-0aea6aa5e45e": {"__data__": {"id_": "b290d85b-1104-443f-894d-0aea6aa5e45e", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8c063bce05baa84284055404aa1df4b715d15639e2b720dd2d1e763d705646", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef70dfe5-9037-40cd-9e61-b01d9d748c55", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020. ", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8860861a0ea20e4c055a6e279ed13d023925bd88edf773f724830f9d537c06df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3062a1-03e2-4518-9cec-79e7256a1583", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "original_text": "2020. "}, "hash": "a1443eeac2e1caa2206e22aa3c5123f8d6bbb5445e499bfb2ae510040e120dd3", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "start_char_idx": 5544, "end_char_idx": 5695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3062a1-03e2-4518-9cec-79e7256a1583": {"__data__": {"id_": "7e3062a1-03e2-4518-9cec-79e7256a1583", "embedding": null, "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "original_text": "2020. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b290d85b-1104-443f-894d-0aea6aa5e45e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three months ended December 31, 2020.  Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland is excluded from adjusted income tax expense for the three months ended December 31,\n16", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b502fa1cd7fd5544debf29d9dcfd84c24ba50e2c1aa7c875df54e47beb8bf518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e24a6d4-3ee7-48f0-9942-93a20dec49ef", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n"}, "hash": "206f41bd7f358f5ee206e0f65a7bb5d5880b8331e65e27aded484f8c95191ef8", "class_name": "RelatedNodeInfo"}}, "text": "2020. ", "start_char_idx": 0, "end_char_idx": 6, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e24a6d4-3ee7-48f0-9942-93a20dec49ef": {"__data__": {"id_": "9e24a6d4-3ee7-48f0-9942-93a20dec49ef", "embedding": null, "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3062a1-03e2-4518-9cec-79e7256a1583", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "original_text": "2020. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415945d27e953fae56d5600fe927cdb31b7fdac9043be7b6bfece2b0894f8c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec9b0eb8-26d9-437a-8835-472f5a021aea", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization. "}, "hash": "b5634dfc2be2c11e4313056dc5eb501c673ba63d4e5c6e3859bc49e9e8664a84", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "start_char_idx": 6, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec9b0eb8-26d9-437a-8835-472f5a021aea": {"__data__": {"id_": "ec9b0eb8-26d9-437a-8835-472f5a021aea", "embedding": null, "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e24a6d4-3ee7-48f0-9942-93a20dec49ef", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e06c0fa404715a459b4a37fa1de29a76079872f05645703beb85a8d524f661cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab35f04-9d59-407d-9f7b-ceb35f015cad", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n"}, "hash": "e94c091c19335090bd85ff13b11bba1b38407352ea95b7c9bb8e548a495acb0d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization. ", "start_char_idx": 250, "end_char_idx": 476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab35f04-9d59-407d-9f7b-ceb35f015cad": {"__data__": {"id_": "2ab35f04-9d59-407d-9f7b-ceb35f015cad", "embedding": null, "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec9b0eb8-26d9-437a-8835-472f5a021aea", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "829b86830da57a88915b22cc76b1746dc6124a08b6c621e00f22e0feebae9286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd4993d6-a274-444a-9795-0db2a8a545fb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "ca924fccbb977bbd2a224af165a5bc53d621228523c4537c1d83bc36b371f05f", "class_name": "RelatedNodeInfo"}}, "text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "start_char_idx": 476, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd4993d6-a274-444a-9795-0db2a8a545fb": {"__data__": {"id_": "cd4993d6-a274-444a-9795-0db2a8a545fb", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab35f04-9d59-407d-9f7b-ceb35f015cad", "node_type": "1", "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "229f8f865c3f0cdee7eb652f0b3116b688ea362bc0008858dcfb4a497e70e254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0423de06-9bc8-4ac1-9358-12a4a9510762", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "e84463288c403670793b22d5f7e72a80bb62258cd303fc789b5af316a212688f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 639, "end_char_idx": 808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0423de06-9bc8-4ac1-9358-12a4a9510762": {"__data__": {"id_": "0423de06-9bc8-4ac1-9358-12a4a9510762", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd4993d6-a274-444a-9795-0db2a8a545fb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a2e2dafbfdb03b6f31c19fadd7d987d4673a905e5646c03d9d8724b232dc7ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94b3f73c-a767-4b40-9fe2-00ac453781e5", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "8ac304d6cb4069de2eda6f5c4cb1ba84d0e6789a732608bc3eb6930f2c5f64d8", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 808, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94b3f73c-a767-4b40-9fe2-00ac453781e5": {"__data__": {"id_": "94b3f73c-a767-4b40-9fe2-00ac453781e5", "embedding": null, "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0423de06-9bc8-4ac1-9358-12a4a9510762", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09cdeaea2a7372b6985c398b126b601b7a111f9e1d5fbafd949e008d8af15f19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88514407-b707-4431-bb63-da1a2873d59d", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n"}, "hash": "447deb52e47120744151ef97abca4f17adcc75ed39a49e45a9584fe9e04e34df", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 1053, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88514407-b707-4431-bb63-da1a2873d59d": {"__data__": {"id_": "88514407-b707-4431-bb63-da1a2873d59d", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94b3f73c-a767-4b40-9fe2-00ac453781e5", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11e71151e86dfd3799e8d0539024f41af0a969fb6fa2a59a65a8f0a552f62235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "9060fcd5ba573fa1fe08b7802f38c0666b64fab155fa7c8f53c32d748f4f30bb", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "start_char_idx": 1507, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1": {"__data__": {"id_": "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88514407-b707-4431-bb63-da1a2873d59d", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e19066178cc44f22defebaf27d33930c448155713e75a6099dca7ec4a52007b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d32585-782f-4b7f-ac90-9607966cebee", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "ba4e0e61d287fd8fa02b3d9460a3e1cf3e5f44d00b55ca2e156c23a05927aff9", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 1905, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d32585-782f-4b7f-ac90-9607966cebee": {"__data__": {"id_": "92d32585-782f-4b7f-ac90-9607966cebee", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e05046b3331752ff55d91d6d82cce346c3c48a6f133f17969b44f0b3302b4e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62744edf-e546-4d2c-9ebc-e8d628868d75", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. "}, "hash": "77f47c7454e33d0aea40f49134fc5b8465f95855914aa417fef59c6d38107410", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 2259, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62744edf-e546-4d2c-9ebc-e8d628868d75": {"__data__": {"id_": "62744edf-e546-4d2c-9ebc-e8d628868d75", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d32585-782f-4b7f-ac90-9607966cebee", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; acquisition-related\nintangibles amortization; employee severance, litigation, and other; and impairment of PharMEDium assets; in each case net\nof the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2bfb57c98c1983055ee3b37f3edb6aea4b4c54bab8f188103677c1735e233d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec740c97-cace-494a-8d9a-0ce19846920a", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. "}, "hash": "ecdb520619dd8cb552efa1b5074d7ec11f79364340e689884ef2f8262b8efac4", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "start_char_idx": 2710, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec740c97-cace-494a-8d9a-0ce19846920a": {"__data__": {"id_": "ec740c97-cace-494a-8d9a-0ce19846920a", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62744edf-e546-4d2c-9ebc-e8d628868d75", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain\ndiscrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act and the per share impact of certain expenses relating to tax reform in\nSwitzerland are also excluded from adjusted diluted earnings per share for the three months ended December 31, 2020.\n Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a043adc0494c4a99581162bb139544eddbb520269599344aee6696cfd5dfcdba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc187a50-349b-4346-8432-add0b6d2c20c", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "original_text": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. "}, "hash": "6524fc4a9c77b014f710b4a404be794ed675936a1849522f191171aa04da8139", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "start_char_idx": 2790, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc187a50-349b-4346-8432-add0b6d2c20c": {"__data__": {"id_": "bc187a50-349b-4346-8432-add0b6d2c20c", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "original_text": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec740c97-cace-494a-8d9a-0ce19846920a", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact\nof the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating\nperformance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47557e5818f072cd76934673f23f3bc5224c194d63d7d8bdfa6ee3148b117d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "136654bca316b6673900b0505e9dc5ae93992c1a4e4c387b489be8cc8009b51a", "class_name": "RelatedNodeInfo"}}, "text": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "start_char_idx": 3076, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6": {"__data__": {"id_": "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6", "embedding": null, "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc187a50-349b-4346-8432-add0b6d2c20c", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "original_text": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "902ba06f1dfbefbc57a7a24d89a57cc7e0ff1ac4cb6218591ba7945131b621bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0848b7e2-467b-4f9c-a280-d44b4d04eae2", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. "}, "hash": "92d28d9bcd90fa1f2c7f5a8a89b6ccca58c6eb927c759d37035f537dfa1c16c5", "class_name": "RelatedNodeInfo"}}, "text": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 3281, "end_char_idx": 3517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0848b7e2-467b-4f9c-a280-d44b4d04eae2": {"__data__": {"id_": "0848b7e2-467b-4f9c-a280-d44b4d04eae2", "embedding": null, "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2021 adjusted\nfree cash flow guidance.  For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60035b794483cc99450e09275b3f0a60d993b41bc6dc9ff0a659e31425bc5c88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n"}, "hash": "6bc54de45947682347743e3ff9dcb734a17b0947c0560dbc3c6acc85784984c6", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "start_char_idx": 3517, "end_char_idx": 3833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a": {"__data__": {"id_": "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a", "embedding": null, "metadata": {"window": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0848b7e2-467b-4f9c-a280-d44b4d04eae2", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4780ce78beee3153d193b13940588aefdae798f95784c0def4cda391e862150a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1911e64b-b2b9-4f27-82bf-c4f80e458c77", "node_type": "1", "metadata": {"window": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17"}, "hash": "a51138b84734d6a13f34211e8f3af74913a92d0c558743c5372b0d20238d9929", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "start_char_idx": 3833, "end_char_idx": 3929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1911e64b-b2b9-4f27-82bf-c4f80e458c77": {"__data__": {"id_": "1911e64b-b2b9-4f27-82bf-c4f80e458c77", "embedding": null, "metadata": {"window": "The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a911e767b947de3430c12d2bcb4ccfd2a336a642355721c3f030a4716909a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2020 adjusted free cash flow of $837.6\nmillion consisted of net cash provided by operating activities of $903.1 million minus capital expenditures of $65.4 million.  The\nCompany does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the\nprobable significance of which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO\nexpense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the\nCompany\u2019s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions,\nwhich cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-\nrecurring.\n", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0aebcf79cc3656110e610833143401ec7cdc37b1cfab15e5d1a59de6e100c86", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210204005165/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n17", "start_char_idx": 3929, "end_char_idx": 4179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"6f69c112-8f03-4ddb-8854-ffb17f62804c": {"doc_hash": "c09b1243cebbce529b32407b2392c3727fc10fb61fd7836733d8defdc0fc9520", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234": {"doc_hash": "dd5c48959d41640f67011896f874e7473caed88e5d52e634da9d059820c1f38b", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "fa32a19c-7633-42a5-aeaa-3658b0e67427": {"doc_hash": "fe757901236494618ef7de0d0e323c9d34b0c5a9c3bd29ad49ef631abb8b3cf3", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d": {"doc_hash": "8ef15e50093ccab65e772d75dc67223025b4a18293818f7312d3b104bffa9fc6", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "9d690e74-07a8-47b4-a72b-2dacf8bd1eef": {"doc_hash": "408ea656625459b6709f01756b9e22ba71967a0e58997ddd8914309c4de2ae6c", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "e13e9bb8-bfa9-483b-9213-1555930281d0": {"doc_hash": "d17592540b6d000a8a960aea331a7d7475ab0958f6b8d3aa4d1a0763b286fc7a", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "dcdb157a-2a24-4a89-a233-fde9af9c7e42": {"doc_hash": "177b3f66df0db52956ebec4514dac4f5ef4d1fe5990e7ca67086ee792e9b3d0c", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a": {"doc_hash": "5d14a681e5fe802ee6058c4fdde64be0c86c00d3d8546675929e58fdbb989565", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "7417037a-f314-4e39-a284-2823f56bc62d": {"doc_hash": "90b0594e5bbaba922d08ce7e37f2e35a3a9d689c024b6249ed474045dc5c8534", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d": {"doc_hash": "3688c503d4aa62ae8429b659e0510faf22825e371735cfa888b6c9e84f259ead", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7": {"doc_hash": "15155b51a9699f3db71617691393f98da8ec74fe9b35abfb713c4d2ed88aa13f", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "3ea926b7-160e-4858-8ac6-aae5af7613eb": {"doc_hash": "3770d535fdebcba401993d60d5b6873afb5897249d06b7149935fcb6b1b064b3", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "692f35d7-bb80-4681-af15-b826afafddcd": {"doc_hash": "dbae34a0e724dda6ded5ef916868d5fd01ae7f944690529c32fdde74142f548d", "ref_doc_id": "125b42a5-1317-47e5-81b5-d9ffd92beca0"}, "2ffcb98f-6650-46b8-8601-fa797536e2e4": {"doc_hash": "a8f76416f3ea961806faf5f695454c43a1fa0b251623e934b9097024a7b52389", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "0a7b60fc-c114-410e-9869-c197ca8ab42d": {"doc_hash": "f14397b15d84a5d1af557d5a1b44a5968f950c4c5f46d108150ade8c91f95ccf", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "1219bdb9-c295-48ed-a2a6-c56d54df34b0": {"doc_hash": "f26b0278d03e4ae71e2ace06c688097998c90ea950670c5a638eef85fa6676d5", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "91df9e7a-64cc-49a0-8860-ab17d2b52a34": {"doc_hash": "f25b4e5d80bb902a2535a1d8d5ac78b869d610f74b5f298c12d0bf429c1c19e4", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "ef290b9d-ad8b-4f72-b718-ff345ee420bd": {"doc_hash": "53505b93c7a6a7d36b2c66e0a08512045e180ab8ee88b66583576f718712dda1", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "2f7e0395-2c0e-4a1e-9871-49677cb799b4": {"doc_hash": "1f144934e06cf58e13fb0312c08f631a7a26ee29de28cafc5585eecffae0ad4e", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb": {"doc_hash": "b4c7ed1d2e91844a8c14b22f3d3ab5f5ca6d6c6719b1cbbe67f376cce653d456", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "453dbc99-d2b6-4381-9de9-45d7e19bf97d": {"doc_hash": "6a2e3e434d7a946b3faadc2520fb04e3409e7d527879f86aa79f484b966df1bd", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "48356261-ac16-405b-b9fa-9fc0083072bc": {"doc_hash": "6aa6aa19bd09739248987ab079befcf43dcf50ea44de254e774c2ce2fb07a566", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "11f2485d-d73a-4ae4-b834-d96dccf0e446": {"doc_hash": "995e1067c9e9c589da287e6a34fa43e51be48df0f37b6de0c16d20d46f0448a0", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "ab4cb473-561e-4c12-95bf-0377bf84ee2a": {"doc_hash": "1b2f7b9b048c81318439f3b561dde4aa1799e997697e32d1c7a470246130ffcb", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "f870365f-19ba-4706-8698-00937306a5ae": {"doc_hash": "6410f3f264746ea7e7ba8cf9efdc6c2d6cd31d73a77387d79eec06d118cfa6e3", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "2b67aca0-37a4-4b66-9fb6-607f3579d200": {"doc_hash": "47efc752de7ea19b5989544c3c2b86cd6ced7acb996902601dda705d3afc1826", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "c5dc3506-b214-4bb6-a916-a5145eaf304d": {"doc_hash": "354857ce87dc102ca44e62efe1204df597579125a563636b24f1a1f43c105b6e", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "31c8c12e-526a-4b6d-a88c-64a9e995e7ff": {"doc_hash": "573c4aa5da52579325bfd0f9f8b9077f5dcc831430d75750764b55b2f6f57ae0", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db": {"doc_hash": "c8723c872de2aa1871dd3a3fc00b15cbe1d0f21de7698a063bba15bf4e7d2137", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e": {"doc_hash": "aa1b077784238ccdcb5ed2f1c089322064bb6a7c84e01456dcc5d5aa0a27f370", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "ad3eb726-fd7c-4875-85cc-341bf7c8439a": {"doc_hash": "cb780252835cc68572586171e0680ce50ccc33f0b85479b4067a94b8de329e09", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "c49b86af-b738-4694-a794-83f4e7dfe47e": {"doc_hash": "e4d38def12467ced4961d4b312e1537e609638d6486211cc370bafaa9cfba204", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "c46aae02-7e92-4594-b2e3-ff6ece49ca74": {"doc_hash": "1202429245b7ba7fd498b3a4c3c4f50c8751f1cd37e4eafcad16e6d6cc8df5c6", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "c96f93c3-dd33-4f5b-b33f-e91847e1fff9": {"doc_hash": "5d02c2f3a26dd9c83f8b93fcaa3956d7118b26f6e57748e55730286d1fb741a3", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2": {"doc_hash": "f9c2c41ecfce8acb9bc42e71181f39d6ff7d1a7f7caed8c3f71baa78921c9de1", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "e3da4f95-4f87-4aa7-b981-a301f729254b": {"doc_hash": "631ba2cbf7209dd4b97fe0465acfa39b5312b400eeb8a19c1da94a6f56ff3d02", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "328694d0-c667-48e8-9f8f-278e4082c166": {"doc_hash": "b68e492523f01d1f6752d9252173c4d5103ae4e4bac5deb539d88178e5934562", "ref_doc_id": "e8b15d60-9ca4-4d47-9dda-ead9cb793180"}, "beb21146-5588-4e02-a365-58585dd278ad": {"doc_hash": "f1ada4f04cb1b6904f08f0dfd9e3f85c0ca1384502100b0fcc010cbedc719a4b", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "4bf4c762-efff-4a5c-832d-cf950aa38e6f": {"doc_hash": "48e90401154d11e537471c5e38e5b987fa0b3d657ecca2bd4ee99714d0ec7378", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "f8be1e17-73f7-4b90-84eb-81b2174b2172": {"doc_hash": "1945488958de201a320f57c26a8493f9bd332779951c0bc0c02b56c5135e9ea2", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "9fdb71b9-b7ec-4c08-815e-064d4f6ec745": {"doc_hash": "2f443772a7b1acbab784a634875ec3e13b8118226e1601d93904df965fd4fe4e", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "a4224b25-439e-48fc-95c1-a1f11acb6450": {"doc_hash": "b6e428625d85f387e501e5db0c8ba58c7f4f5476ce3cf5d49ebf5d4cb84c7a77", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "1149b373-3242-4ac3-9f05-ef8cf343ce5f": {"doc_hash": "201ddbc8ea12aa14992fca6cae87b31556c2a1813438548c64828811a0b5627b", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "a4da8643-2e9b-4e89-a34c-208c098af54a": {"doc_hash": "96797d4a2f7952ee67f6924be235a1eeec96043af0372093ae9c9d5c75048e86", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "6cabdf4b-ef78-4533-9829-0000e095fd16": {"doc_hash": "8745e7405f4a4202b3c74865aefbe38a87f180e20a71485c6225a2798cc8b862", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "44bc8c7b-822e-49cf-b262-6884e83fa12d": {"doc_hash": "b877af485d591938a73ea3674581d3e5c6335079141220bd4ac705807d4c0df2", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e": {"doc_hash": "e0af099f42ee2fc3107621854df51f4bcf2a1a1c5ba3ee847dc3e8bb3dfce00c", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "d90bf804-aa49-48b7-bab1-147f41080076": {"doc_hash": "34ba444463c3f913b8088f2332390519b73ffac39b6f99ad34ec20205c3c33cc", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1": {"doc_hash": "478a4b8be2c1c9c3b1d8801ef0d79fca7e78bb3fc3f9e5eab535bb8a68ccc036", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "5f46a392-5691-4f94-9a2c-032e1f6d1e88": {"doc_hash": "345039644a3d942b858038ede26ae03ccd8df1b55585fa856dda683a4e527589", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "1b52b6ae-8856-4745-8502-342145c4e9a0": {"doc_hash": "648857727519f26de1e603fa6acb22785cdc4d271cb650b7a52e3be17d219d9e", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "f6398591-5d14-49c1-b8ec-1b8b29836f55": {"doc_hash": "f71ab5d3b4d8fa4ddccfeb541af0ca401bd5ed1e3f2fb11700b1314518aec4ea", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "7e2c3695-5340-4a76-af0b-477098cd4360": {"doc_hash": "b434a5b7e243a836edf6bc671c6137098ef4ac33da5861d8c0758ac27a6558e6", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67": {"doc_hash": "da0437cd53ade521b79d0ceeba592f345e0551a5d9ecefc8851adfe2089d4cfc", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "442d84bf-04ec-46c9-a865-46816f1ac4f7": {"doc_hash": "dd07ca6b00ef1aac1ea56f1de751f67c4024b24f3d72965d71975ba94cf03265", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "b74692ba-ec0a-4ea5-9f13-4095f9e59582": {"doc_hash": "07ce23cf597611eb383f580bbd3fabf036a9aa9ae51123080f5cf48e374622c7", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "dd4531b7-9b2e-4647-b071-0da772f1fba5": {"doc_hash": "1b477bd75efb27488e9bde6c8291c6d590af90e8900589c67fdc8d23a68f1bc6", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e": {"doc_hash": "c6383549be2d2c71b7420a799740a47a90e6452b82e6498d3fc09bd3d64bcdbc", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "d6bc1dff-a395-4849-9aa8-4b99ae582c2a": {"doc_hash": "6ed70bacc4bfd004e384abc975030801a4db134102d6f0e54015a7eae04a667a", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "6d014538-f3bb-4dc9-aff6-8d9c74f97361": {"doc_hash": "f907e96339ac38fd8f2205a39a1887c6861ed0e054aba5e91b0b8119f9579d26", "ref_doc_id": "acb30ac3-d30e-44aa-93a3-2c8dddaafcff"}, "5fda1dbb-fb44-43ef-a357-4a80759919f9": {"doc_hash": "42292c3c375fa8fb65089f4d0fb96cb22f6e6a25a5fd32a6c2f306b243d00cb4", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "a7ecd1b1-5f92-470a-8809-029d137031d0": {"doc_hash": "2abf5323ce7f7dcb52ea6db8b48cb75c9768535c81b1cdb2e4f226bc3de9e38c", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "e6628ecf-b882-4912-9221-43e529f3e0ac": {"doc_hash": "ed5f25d7914bc192f9cbcf49e433e1912f8394389591f7e3cb2c686dd39150d3", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "4454308a-0f3d-473f-a59a-12ce7f85c7d5": {"doc_hash": "3d6d281b597a5066b20e505660052be9db5a8cbccb30e1f4936d89e7fad57582", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "697b6516-3e39-4429-8309-8044f55ebe9a": {"doc_hash": "a85a2006798a5b46fe3a47dcb404aad6e9bbf586e4a3d9e3a75ade41d7d2d45c", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "9babbc5a-e87d-4626-a360-f5bc6572ed6a": {"doc_hash": "049eff125a14bbb6c4c9af05487fcac143142032f46a1a3003fcdd305c89647c", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed": {"doc_hash": "da98f2cac5ca852fd63cc26fde8427e5a5ef151cc84155661e802097aaf8e428", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "d644ed76-c4e3-47e1-b28f-7369c219b51d": {"doc_hash": "1b7dccd14b4d2053a47ef17a3b1ce80da285b0b00f1b5737b058e5e4bae10655", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "d5e5d013-fd50-4fce-84ed-b8af97244d4a": {"doc_hash": "4fb1ce2677e1e26aca46fb7a5d995f23a563e5a96ea16a6123c59b2feaa3f456", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "b7857981-5452-4e12-9ef5-9bab4fe6fa35": {"doc_hash": "c9107d2148686e478cec4de37132ab443ca371d5177291bd7f758a8c1de2bdf8", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "9cf4b884-4421-4078-9ee4-151813c0660e": {"doc_hash": "8bad6be80025f21d5b044987f2a5be2b442d131fd6786534ecc3d0722d19116b", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "54400107-fb68-4ead-b71b-9adb708c45f1": {"doc_hash": "3eb794c07562f475f99292e723ba3aae6f9b43a6fd84bc74a910addfddbb21a8", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010": {"doc_hash": "12cc269049d323b23f015e07cd6caabf9809bc7e1d5c3570e513468821c17857", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "1154bdff-19dc-4a94-a2fb-d6624d64aa1c": {"doc_hash": "12d961eed0d93f8a76da17bff55f95700cb045f02dc9da2255944b1ef05d7c28", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "ca5ace25-441d-4f28-8d77-27dc3d72b637": {"doc_hash": "1f396cc32ff676ee70ec330de8506f478c185957780debbc86694a1c069e7cfe", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "3544bf7b-bf7b-4831-b4d6-060344f97e87": {"doc_hash": "d56324ec56a1e4f63e405c3e9b1ec23969518f2ad1304051b92785a2dc953d44", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2": {"doc_hash": "b556b992e7cdc15258e0ce3bcff02e14742b2cadbf2a931babfbbab6e3149e19", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "30d21c16-4e84-4771-b69a-9ae86bab8d53": {"doc_hash": "c76b28d5b189af92ec0c3413ae721c1d0cb2e92a3063a2a387ec6688fb6c2b09", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "18e89691-7467-4070-b609-0de488c8bbf1": {"doc_hash": "f8f35528dc5001dc7460006964ec6d098d2af2c6f4f37a61f3b1efed601ce803", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "86be27aa-3e4a-4c6c-a17f-3d4365367925": {"doc_hash": "1db2d1194aee5dc0a41384c493f53794c1e1a6bb7644b63a6d1c17bfa5b0979f", "ref_doc_id": "ccc604c0-e4e8-424e-b0b9-158446e69edc"}, "9d825f28-28b6-41b5-a503-82ea206393a6": {"doc_hash": "d613ef1722ec6bcded8351e0fbe59b67a1bbe332aaf3043390fb990b9e34fb55", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "af979747-1541-4a63-b886-80b942b5e7dd": {"doc_hash": "e52f2d8d70c574f0e4b03471c2eb3ae0e2753133092a0e627d92168a162187a3", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "0ab0a858-f5d0-4f9d-9649-2513b3934861": {"doc_hash": "66c94b80419cc50e2498a9f604d0bb0172b517d221344ef93c9e0465169f6823", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "32129d5e-5441-400c-ad87-d3e6663675a3": {"doc_hash": "022083c345f5ca756af537ae6a5e1940a5efabc395bbac951cd84e012a8baf31", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be": {"doc_hash": "9eba3be5954eeb0a9311ef9836edd8e55818ac2f928105f8617c44917dbb062a", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311": {"doc_hash": "567718ce09a235516c59d83d30db3a76390f66370e7c6c7151d97a5564b810fc", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b": {"doc_hash": "378fc31caabd87397d9cc15005ec5b0d7994b4d99a770ac27b81220cc5b5cba9", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "7847a9ae-ae82-449d-b4a2-d16ca3f7983b": {"doc_hash": "262ee59ae985b01c362d9a9abc1fd969d7e9b4a7327d9a5391057fde37c30de6", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58": {"doc_hash": "43ce278a4fa0e5291b6a3d6c9733c40d807b3a966157dce0be3abcb597391ab7", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "20bfb039-f257-4d6c-817e-48b47fe7f7e3": {"doc_hash": "0c2691c11ba1414e4547efbcb611d3d2323d64bd38b4eadad7f5b287f23201a0", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c": {"doc_hash": "daf4dd39de7c6a771f9fe1c61f9469ab1833101b770cd7e34fcda68e2deff717", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "aa50dc57-e016-4485-801a-d123966977b2": {"doc_hash": "eb84a0fb7df99cb6442b995d7bfbf70927991ed1d103e1ea36d652d38b271806", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "a6cec582-1c3f-4367-b6a6-014661776111": {"doc_hash": "7565ed7c894a08198993a73049509d74b1bcd136490300f5e520bf2742384729", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf": {"doc_hash": "d18590d48cf96d8009a3b71514fdba0704cc5d4416c0a75f96991a9837ea1e51", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7": {"doc_hash": "cd70e82c452a2f0fb905ef41703db355c7e5c9d7f64fd896ea4fc6eb94e6e964", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "e480971d-b011-4a97-8220-8e7c7f83c5d8": {"doc_hash": "d00da3fb88188977477ea9bf2f92bc1397731b1d68b4972014d09b182dc94ee4", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "ca0babba-9681-448c-80d6-9472b1448f81": {"doc_hash": "73302fc9b5705169c08dc0a761173df7b7792128fb828ad03b113e3b39d0cecd", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "3aeec7bc-adaf-4b5f-bad0-f53d95416544": {"doc_hash": "b627721db54eec8483e87b062a912d4e57c52ac2eaa9cd34d83470928497827a", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "6ea93543-d1fa-46e7-bd9e-6159ce6e27be": {"doc_hash": "6c913fed272dee98f995fb8e55a38e4e2ad1dc882268b5d47d7b09190aa85114", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "d69f50b4-c207-4c43-903e-9acd02e9c392": {"doc_hash": "a53ea747ee102acb8f88c990cbf59e03ddb1c1134986744e84e205ec1e463262", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "a4408110-3196-40bd-8b09-6cd9012762e1": {"doc_hash": "058b9f10832a39b6032445030c47f8a1342fe581682676b4ad68e9f526826925", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "9bcfdd72-e566-43bc-ba00-88f6d1a24064": {"doc_hash": "ebedb5179126565bcf49b0b12b82c99857e74809c5342155b30d975813d43580", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "70091946-07df-4e1b-ae40-550f67a0b2e9": {"doc_hash": "e37bb0ea8a3e9175251a66267f063760e1d2c9eff5c13c1833e95abef0577235", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "e165a69c-36b1-41a8-af08-661e0ddb4ce2": {"doc_hash": "48df22284de4c868fb8a2d7882e93de9b4afc30b9eecbadee1961ab69a8d4377", "ref_doc_id": "692baae3-a27e-40d1-aed4-3d47ebb6db18"}, "1f9fb7af-9747-4709-b93d-5341bd64c0a9": {"doc_hash": "42e7340c497b956950b14da078d2f5f78436137211c1efa2936009a56794e478", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "ed99e983-27cb-4134-b209-c20d8867fdce": {"doc_hash": "11977d2e77efc1c8b2cdaa2e9a5820a709dc0c78f2da7e9398c6f6d618e6cc72", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "c353602a-d05a-4da8-8802-4cb019f258bc": {"doc_hash": "6d246a2b7b5cc4c4d647e966774509b7d0165fb2621d83ad22accae81c4da329", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "a7af88a5-8758-4465-8187-7b96ffa71bc1": {"doc_hash": "cc9daf02a5def31726249bce5e44a6e4638b2ecf6cde5b305f8f6a65f2721e30", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "bfed1781-bd80-4dfd-bd41-9b05a3718727": {"doc_hash": "ec1dc466806141f42613f01c4dd857803a0913c9dad027f120c4ea4f92b21196", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "4a8428db-e65a-49bb-8bcb-1b0093c86637": {"doc_hash": "5e166c9bd482b2b829da0769a85a71cdaa5e729ffb81f6d21d837552b0419d76", "ref_doc_id": "84eac33e-a33c-4491-92d8-95e95fe53864"}, "bf42674f-7fcc-4894-bd3b-f40409f5684f": {"doc_hash": "4f962aceac165634d0bbd4625d42c918f7e95d131bbd1634514d30f6a85c996d", "ref_doc_id": "fc7aef28-971c-436a-be01-5362f39dd466"}, "a63e6680-ccce-4a5b-8dae-c8f387a1bddb": {"doc_hash": "d326abc817c0403c96119f5ef3391e5b22c40b724c219ee5a400b1c0b3ed3767", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8": {"doc_hash": "c8c627c3c2569e37bbe51024a622c33653667cc1b54e0ee2b4646ad03885beb8", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "daa67c4e-9122-4a5c-a37c-500f10fa8ccb": {"doc_hash": "bf63d1ca992536e0f049fa4367c7bffb07fafec49a69f23d95f9ae284c6ffcef", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "e025f58a-f885-4d76-b95f-f50a1ebc1d3f": {"doc_hash": "2323db4785b18c8372c2b9211fb7e298c4b44505380631240a4bcba9ce3db2ad", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "bbe54f4e-acfb-4093-80ec-67f9f21e6eac": {"doc_hash": "07a754fe2c1ffb1ff31fa1f3870619b6accd87910cf5fe705d250c9390f1a376", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "e2a6226f-273f-4013-b375-9a3c4dcb88b4": {"doc_hash": "7594552572034ff1104ea05f8312619f8df7ae5511288873185bc4ce0ceef325", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "19af3282-8035-4007-9576-d25c930021c9": {"doc_hash": "2c65f31d8f24fcd8b43b25168f39aad5f8dc48c41c93d624f7562070edba88dd", "ref_doc_id": "e890ed33-efcd-4274-8eac-0080349b36c1"}, "2822c04b-080f-4470-9eb3-f0395d7a9b8f": {"doc_hash": "2e085ff4154433943b570d126942bb616c74c924125412781cd21291559bd5b2", "ref_doc_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de"}, "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2": {"doc_hash": "dd33ce6773110d1b303c1ab6a03f75528617f3b1a657c3c671381d2193ca5413", "ref_doc_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de"}, "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f": {"doc_hash": "c584b8688a1f2bdfe1086b73c3ff01e66a3f43d2078667898574f5b8f9bfe5a8", "ref_doc_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de"}, "7c514b4d-8591-4437-855f-b64c3acadc2a": {"doc_hash": "1dae897c2eb6fbc8f6a89dce4915d0168a27b793a3b9050ca24dc7f3727af586", "ref_doc_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de"}, "3f39011c-4fd3-48dc-b849-e05cfdf7b170": {"doc_hash": "dca07192c8421b6e7a47701ab1c3b80ff61aff2b9248e27644cfd4abbb53998f", "ref_doc_id": "e4a6b124-21f7-4ecf-97d0-33b1f78e44de"}, "746b0dcd-4cf3-46a5-a942-05df0ebc517c": {"doc_hash": "686fa5b588cbee821303b95f69546bd1818df19cecdff3a4acedb75e7534d4df", "ref_doc_id": "eec2445c-cf61-4e0c-a8f6-0696315e2372"}, "1cb8bbc7-5258-486a-bae8-040bcb738fa7": {"doc_hash": "9daf84deec48a2d775b0eb9260a19e8cf245dea49a1dd0c1580d19363efc4483", "ref_doc_id": "0f62ec19-fd05-455f-addb-ba03898826c4"}, "ee3a9dcd-544b-42fa-8436-60d4a50fdccb": {"doc_hash": "110b146d3192985fbee5069d3342ae9f5acbee101341e0bdf24235ba5bd640cf", "ref_doc_id": "0f62ec19-fd05-455f-addb-ba03898826c4"}, "0186fe30-ba76-4ed2-a63f-9ce90a282e03": {"doc_hash": "4f228b3f55e785ea992c7e1b617c7cb9142a8a062c4e08fe3234c98a4fed0df9", "ref_doc_id": "905f0978-1ca4-4ec8-b37d-9be865985c83"}, "2f22a854-b0b3-41ec-8742-fc1a908e36b3": {"doc_hash": "4b80e3c733d21d6c577c78855a14b770ca04443e38cc3661d1e406d7fb87b289", "ref_doc_id": "905f0978-1ca4-4ec8-b37d-9be865985c83"}, "a86f974c-1137-45d1-a550-b5984c307bbf": {"doc_hash": "ce1c3583bb6bab960cbe2e2e4aab627f6cc41cefbb4909ac07d6cb64bc849285", "ref_doc_id": "1c2f3d50-6806-4b33-9c9e-674d04e0c4e9"}, "f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2": {"doc_hash": "e4f2d64c486100b5e348355488c6097089622d12ade06065648620877c5e4817", "ref_doc_id": "bc8e7659-908c-4294-9764-5ea7ec58ac51"}, "6815612f-ae64-4430-83f4-fb5986dff386": {"doc_hash": "c7e12f812b86fa7e675475f11b6cc836d171fe5396cfe50084fb072de6709c2b", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "5c1b1223-6b4c-4773-adf2-533bf8f8b890": {"doc_hash": "b5e27f030b04b5b806b516a6405843c7b4e1e081cff014bf443a959fed9729fb", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "cf9c1c70-c9ed-4a92-8759-25342e2b7646": {"doc_hash": "efc2a86a3ca4a625203a65d844b2c893534f5ad0bf8d188d22c0f2e224bc77e5", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "cb46ada3-e5a6-423c-9d44-5355478b35de": {"doc_hash": "9c5b53c3270a624541fa6b760131151a9691b7d4b268a9001be105317df921d2", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "a061a161-e183-44aa-80b2-6d40d309cb23": {"doc_hash": "4ddb1556ff803cd8b3af31e92f64527c64a2cb7bd9554691b6dd3734b4a4cd97", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d": {"doc_hash": "f4bf620602b0d8ed3661c1a0c964abadb83b3255388091e0944e1c88cc381d4f", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "62e0b680-88bc-4940-9ef5-d81b34db8b38": {"doc_hash": "3a35c6cd81a682514095e2edcbc0273ce2ba836ea819cd1032bfab835d38ae7e", "ref_doc_id": "b8f69e19-0d12-45de-8d0f-502d5ea5015b"}, "0a34a9eb-058e-4aea-9e7b-e3e7638ead5b": {"doc_hash": "d48281dac723f3f25b04c468a0d41ded6349f8d05cbfe7b16333080bab484f1b", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "8893fa00-3af8-42e7-85b6-30bfaa87a7c6": {"doc_hash": "0a3868d8671bc6d279f73aaa1eaee0d4b16ce9624b415fcd3dcbd8f2f16fefc9", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "3ff58101-ede1-444d-a9a5-dc233958d615": {"doc_hash": "7f56fd7378c74c5b80bd9833aa88f4e8d5e7a06001ab7040dbfb4c44023c76a3", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "83c7e74d-0b9d-42d6-946f-80396d8cf8f5": {"doc_hash": "91a74d71f1c08f834130955531194772685c3b0c17fe8e63ee35f22198773768", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "dadeb5da-8514-4d83-b336-cca43c918eba": {"doc_hash": "e5aef93860be3a7c7e3b17118e5d078e794477bdfef158ae9356cc4469d0a97c", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "ec448e0e-572d-4f64-afaa-e70c12c282aa": {"doc_hash": "12d4014177c2c34fe1809ec0e17cb220123822d43feefe75782df47c658209c3", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3": {"doc_hash": "da53e11c805853c22e24997ef79e4acdcb691031c8941fb81e5b50ba4eec64d8", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "a75d4af2-4a48-4d61-b575-c4b00c8e3670": {"doc_hash": "ff4d9b3d651214c2d41322e42246ea0a8cd902f1c4a44d7ed5eacf9116a72e85", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "c5e810e9-b36a-428e-800c-4b6d1e809017": {"doc_hash": "366b3b08981b278ab07c4d9e38115ad0132f2d6203d7aeca8a3eff24bc0d9bbb", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "991a55fc-751a-4c88-a743-c100c0be8581": {"doc_hash": "ed265604353d378cda6d886d7f308fa8bfc5929f463ab9fdf5544a53d48782a9", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "7f7ec767-b846-40f4-b379-ebac435a6bc1": {"doc_hash": "018b2cdbeef8fa92042f33fc5569e280099fc48559f39ecf8e17216b77b23a57", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1": {"doc_hash": "10ee073239ba75fbd820dc5e57645e783ea93558627e45648902a9feda5255a8", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "6d1d27f1-3816-4b1a-a937-9af0cce13bb9": {"doc_hash": "77815e5b71dbe2b8bb6ef5df7e60728a5616f63bc2782bae40a5607a3aa71f1c", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "e6856b82-cd85-4e6c-84fb-167c8a794668": {"doc_hash": "fade6287a2af7008be08cd788112d11dc2fac837cd356b914fbf0ef542634efa", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "f6980210-6d86-4e4d-a93c-3f1ace73c07d": {"doc_hash": "4d9e2f64ceb067fa27d25d8790daeb4aa87fa35f57682eabece6bdef91ea3e9c", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "425df418-507c-4cd9-8cdd-b83fcad6a616": {"doc_hash": "d217a5a0bf0debc86190e0739a45757d9c87cb268993b339c57f1d94c85bf719", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "8c6e57bf-4883-4410-92f6-ad3113ab280b": {"doc_hash": "ffa54f97dc6d8ed3788322872f5b1c612c9f2a180c8ff42633d09a5fc0e8f91f", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "b0d87a1d-ea02-46f5-a774-5338ea943afb": {"doc_hash": "594c2c453ec936428cbd526e1d5801351c2e84d724d98b7d7f104c9916b212f7", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "be542bb2-4949-474b-a001-f20f55bce10f": {"doc_hash": "cd7e8f9d9ecc26942e858067776932e80ca71f2da93099005445a61bd5f0b5fd", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "9e1677e3-4e65-44d4-be26-2e51ada0077d": {"doc_hash": "bdf9274c2369e24a0a60da04e1fff820ebb069ce337218faa789d69813ae720e", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "b8615859-1b92-4f9f-b4c2-b2525cac831e": {"doc_hash": "5adf4ab9786db90d872d234e5b55bfd082ab4e75acc18376af5b29dc90eb896d", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "e42a445b-bb21-4e87-862f-efefeb9aa399": {"doc_hash": "0c4ac53fe82d1d393ada03c02f3a9295ac00a035956cc9c8ca1bf0fd99e1d999", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "9d186b80-cde7-4802-a1df-d352a9d47bef": {"doc_hash": "a87cd9ffb5200a6627918384b6e7034ec78773ff5f91e02918cb5a0fa52b101f", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "677c71d0-f3a7-41bc-b088-74c61af5243e": {"doc_hash": "af1ae662e681ba030f6e5f32b5003a8a88ecbb1ce53bb46397541d2b3f57ca9b", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "3ee12c98-a69c-4fca-990f-d3e1124df261": {"doc_hash": "0f32b8a42071f5a3f0a9db6970ee437afcf8f7adbc1a715f2d67cc87311af853", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "7ed7bc3a-f046-496d-b8e4-892b60951963": {"doc_hash": "786051eacde3fa80dccbc86a678aea2f75a1bd3bfa277f62cb56874d44a3a72f", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "676181bd-cda9-42e7-a030-6d29a57569ca": {"doc_hash": "6ca57f43ab1f598d4690297e85dc6317d88416ba3b578d13da5edbab6a915496", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "69e69e26-3fe1-4489-b6a6-e1c34513b742": {"doc_hash": "caeac0c73c20c0bdfbff6275ff676c0fbf86596414a1360e4c8c3bec27e59c28", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "ef70dfe5-9037-40cd-9e61-b01d9d748c55": {"doc_hash": "8860861a0ea20e4c055a6e279ed13d023925bd88edf773f724830f9d537c06df", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "b290d85b-1104-443f-894d-0aea6aa5e45e": {"doc_hash": "b502fa1cd7fd5544debf29d9dcfd84c24ba50e2c1aa7c875df54e47beb8bf518", "ref_doc_id": "af28ec91-33fa-4dc4-af17-9a2f6d4b857c"}, "7e3062a1-03e2-4518-9cec-79e7256a1583": {"doc_hash": "415945d27e953fae56d5600fe927cdb31b7fdac9043be7b6bfece2b0894f8c8a", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "9e24a6d4-3ee7-48f0-9942-93a20dec49ef": {"doc_hash": "e06c0fa404715a459b4a37fa1de29a76079872f05645703beb85a8d524f661cc", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "ec9b0eb8-26d9-437a-8835-472f5a021aea": {"doc_hash": "829b86830da57a88915b22cc76b1746dc6124a08b6c621e00f22e0feebae9286", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "2ab35f04-9d59-407d-9f7b-ceb35f015cad": {"doc_hash": "229f8f865c3f0cdee7eb652f0b3116b688ea362bc0008858dcfb4a497e70e254", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "cd4993d6-a274-444a-9795-0db2a8a545fb": {"doc_hash": "6a2e2dafbfdb03b6f31c19fadd7d987d4673a905e5646c03d9d8724b232dc7ba", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "0423de06-9bc8-4ac1-9358-12a4a9510762": {"doc_hash": "09cdeaea2a7372b6985c398b126b601b7a111f9e1d5fbafd949e008d8af15f19", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "94b3f73c-a767-4b40-9fe2-00ac453781e5": {"doc_hash": "11e71151e86dfd3799e8d0539024f41af0a969fb6fa2a59a65a8f0a552f62235", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "88514407-b707-4431-bb63-da1a2873d59d": {"doc_hash": "3e19066178cc44f22defebaf27d33930c448155713e75a6099dca7ec4a52007b", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1": {"doc_hash": "e05046b3331752ff55d91d6d82cce346c3c48a6f133f17969b44f0b3302b4e58", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "92d32585-782f-4b7f-ac90-9607966cebee": {"doc_hash": "e2bfb57c98c1983055ee3b37f3edb6aea4b4c54bab8f188103677c1735e233d0", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "62744edf-e546-4d2c-9ebc-e8d628868d75": {"doc_hash": "a043adc0494c4a99581162bb139544eddbb520269599344aee6696cfd5dfcdba", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "ec740c97-cace-494a-8d9a-0ce19846920a": {"doc_hash": "f47557e5818f072cd76934673f23f3bc5224c194d63d7d8bdfa6ee3148b117d1", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "bc187a50-349b-4346-8432-add0b6d2c20c": {"doc_hash": "902ba06f1dfbefbc57a7a24d89a57cc7e0ff1ac4cb6218591ba7945131b621bf", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6": {"doc_hash": "60035b794483cc99450e09275b3f0a60d993b41bc6dc9ff0a659e31425bc5c88", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "0848b7e2-467b-4f9c-a280-d44b4d04eae2": {"doc_hash": "4780ce78beee3153d193b13940588aefdae798f95784c0def4cda391e862150a", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a": {"doc_hash": "b0aebcf79cc3656110e610833143401ec7cdc37b1cfab15e5d1a59de6e100c86", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}, "1911e64b-b2b9-4f27-82bf-c4f80e458c77": {"doc_hash": "2b24233ec14a2f57cf20297da17c815dee63f6d067cb15de0d6c5ccb439da3bd", "ref_doc_id": "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647"}}, "docstore/ref_doc_info": {"125b42a5-1317-47e5-81b5-d9ffd92beca0": {"node_ids": ["6f69c112-8f03-4ddb-8854-ffb17f62804c", "5ea55d8d-7c19-4cb8-87a1-de4ef5ebe234", "fa32a19c-7633-42a5-aeaa-3658b0e67427", "d3d2a1a0-7f6e-4745-a0a7-ad48031d672d", "9d690e74-07a8-47b4-a72b-2dacf8bd1eef", "e13e9bb8-bfa9-483b-9213-1555930281d0", "dcdb157a-2a24-4a89-a233-fde9af9c7e42", "e1c8c513-ecbb-4c8c-848f-4d5e98a8be3a", "7417037a-f314-4e39-a284-2823f56bc62d", "7eb6dd64-5ab6-4401-81a3-e3e517b2ff1d", "e58c4e63-32b2-4677-80f9-9ac6a19a2eb7", "3ea926b7-160e-4858-8ac6-aae5af7613eb", "692f35d7-bb80-4681-af15-b826afafddcd"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.81 for the December quarter of fiscal 2021,\ncompared to $0.90 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described\nbelow, increased 24 percent to $2.18 in the fiscal first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Fir st Quar ter Results\n2/4/2021\nRevenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted EPS of $2.18\nAdjusted Diluted EPS Guidance Range Raised to $8.40 to $8.60 for Fiscal 2021\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first\nquarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e8b15d60-9ca4-4d47-9dda-ead9cb793180": {"node_ids": ["2ffcb98f-6650-46b8-8601-fa797536e2e4", "0a7b60fc-c114-410e-9869-c197ca8ab42d", "1219bdb9-c295-48ed-a2a6-c56d54df34b0", "91df9e7a-64cc-49a0-8860-ab17d2b52a34", "ef290b9d-ad8b-4f72-b718-ff345ee420bd", "2f7e0395-2c0e-4a1e-9871-49677cb799b4", "8ef6f4bf-14be-4d95-9b1c-eb80e39985bb", "453dbc99-d2b6-4381-9de9-45d7e19bf97d", "48356261-ac16-405b-b9fa-9fc0083072bc", "11f2485d-d73a-4ae4-b834-d96dccf0e446", "ab4cb473-561e-4c12-95bf-0377bf84ee2a", "f870365f-19ba-4706-8698-00937306a5ae", "2b67aca0-37a4-4b66-9fb6-607f3579d200", "c5dc3506-b214-4bb6-a916-a5145eaf304d", "31c8c12e-526a-4b6d-a88c-64a9e995e7ff", "fb804ab0-18ab-4c1b-89a0-e5361d8ea8db", "02a6bec7-293f-4fa9-b211-75b6f5b1cd0e", "ad3eb726-fd7c-4875-85cc-341bf7c8439a", "c49b86af-b738-4694-a794-83f4e7dfe47e", "c46aae02-7e92-4594-b2e3-ff6ece49ca74", "c96f93c3-dd33-4f5b-b33f-e91847e1fff9", "bf52f489-8a39-4fe7-a4f7-ed0a6f7bb2b2", "e3da4f95-4f87-4aa7-b981-a301f729254b", "328694d0-c667-48e8-9f8f-278e4082c166"], "metadata": {"window": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2021, revenue was $52.5 billion, up 9.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.7 percent increase in Pharmaceutical Distribution Services revenue and an 11.1 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $375M $451M\nDilut ed Earnings P er Shar e $1.81 $2.18\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "acb30ac3-d30e-44aa-93a3-2c8dddaafcff": {"node_ids": ["beb21146-5588-4e02-a365-58585dd278ad", "4bf4c762-efff-4a5c-832d-cf950aa38e6f", "f8be1e17-73f7-4b90-84eb-81b2174b2172", "9fdb71b9-b7ec-4c08-815e-064d4f6ec745", "a4224b25-439e-48fc-95c1-a1f11acb6450", "1149b373-3242-4ac3-9f05-ef8cf343ce5f", "a4da8643-2e9b-4e89-a34c-208c098af54a", "6cabdf4b-ef78-4533-9829-0000e095fd16", "44bc8c7b-822e-49cf-b262-6884e83fa12d", "4009fe94-e4ee-4c94-b9b7-fa76e0e0279e", "d90bf804-aa49-48b7-bab1-147f41080076", "1da4b6d8-617b-4622-9639-0ea3cbc5c6d1", "5f46a392-5691-4f94-9a2c-032e1f6d1e88", "1b52b6ae-8856-4745-8502-342145c4e9a0", "f6398591-5d14-49c1-b8ec-1b8b29836f55", "7e2c3695-5340-4a76-af0b-477098cd4360", "1cb06507-9bc1-4af4-b2d1-f0a7fd586d67", "442d84bf-04ec-46c9-a865-46816f1ac4f7", "b74692ba-ec0a-4ea5-9f13-4095f9e59582", "dd4531b7-9b2e-4647-b071-0da772f1fba5", "dd33b2bf-d7ba-4f96-ace9-eba09865dc1e", "d6bc1dff-a395-4849-9aa8-4b99ae582c2a", "6d014538-f3bb-4dc9-aff6-8d9c74f97361"], "metadata": {"window": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 first quarter was 1.54%, a decrease of 2\nbasis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 first quarter, adjusted operating income of $616.9 million increased 24.6\npercent from the prior year period due to a 26.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 16.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2021 first quarter, an increase of 14 basis points when compared to the prior year quarter.\n", "original_text": "of 8.3 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and administrative\nexpenses. ", "page_label": "3", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ccc604c0-e4e8-424e-b0b9-158446e69edc": {"node_ids": ["5fda1dbb-fb44-43ef-a357-4a80759919f9", "a7ecd1b1-5f92-470a-8809-029d137031d0", "e6628ecf-b882-4912-9221-43e529f3e0ac", "4454308a-0f3d-473f-a59a-12ce7f85c7d5", "697b6516-3e39-4429-8309-8044f55ebe9a", "9babbc5a-e87d-4626-a360-f5bc6572ed6a", "dc2d1e3e-7ff4-44df-bcbd-af190fec10ed", "d644ed76-c4e3-47e1-b28f-7369c219b51d", "d5e5d013-fd50-4fce-84ed-b8af97244d4a", "b7857981-5452-4e12-9ef5-9bab4fe6fa35", "9cf4b884-4421-4078-9ee4-151813c0660e", "54400107-fb68-4ead-b71b-9adb708c45f1", "7d8bd9ba-06cf-4b64-9e5a-55079a7ca010", "1154bdff-19dc-4a94-a2fb-d6624d64aa1c", "ca5ace25-441d-4f28-8d77-27dc3d72b637", "3544bf7b-bf7b-4831-b4d6-060344f97e87", "8af8d10b-c050-4bf7-a9f0-3fd813d5b8a2", "30d21c16-4e84-4771-b69a-9ae86bab8d53", "18e89691-7467-4070-b609-0de488c8bbf1", "86be27aa-3e4a-4c6c-a17f-3d4365367925"], "metadata": {"window": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination.  To support access, AmerisourceBergen will serve as a network administrator and place orders with the CDC on\nbehalf of qualified and eligible Good Neighbor Pharmacy and Elevate Provider Network members.\n AmerisourceBergen continues to play its key role as distributor of antivirals and antibody therapies used to treat hospitalized\nCOVID-19 patients.\n AmerisourceBergen continues its work with the Department of Health and Human Services to store, manage, and distribute\npharmaceuticals for the Strategic National Stockpile.\n", "original_text": "Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19\nVaccination. ", "page_label": "4", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "692baae3-a27e-40d1-aed4-3d47ebb6db18": {"node_ids": ["9d825f28-28b6-41b5-a503-82ea206393a6", "af979747-1541-4a63-b886-80b942b5e7dd", "0ab0a858-f5d0-4f9d-9649-2513b3934861", "32129d5e-5441-400c-ad87-d3e6663675a3", "aae3eaa6-6d8b-4c13-a76d-0a8cee2759be", "96e0a1c6-bb24-4bf2-90ef-fad25ea5f311", "34ab2ae7-37b3-4b99-b8ff-4aa74b4b0c2b", "7847a9ae-ae82-449d-b4a2-d16ca3f7983b", "7b898e6f-3aab-4ad8-8de0-fcfe9da83a58", "20bfb039-f257-4d6c-817e-48b47fe7f7e3", "dc007afe-3911-4b0f-9e8b-ef1ed467ab7c", "aa50dc57-e016-4485-801a-d123966977b2", "a6cec582-1c3f-4367-b6a6-014661776111", "6e4b8d14-a29c-4cc3-9405-538afb3c5ddf", "fc4f40e7-c332-4d4a-8dbd-c8798aa146a7", "e480971d-b011-4a97-8220-8e7c7f83c5d8", "ca0babba-9681-448c-80d6-9472b1448f81", "3aeec7bc-adaf-4b5f-bad0-f53d95416544", "6ea93543-d1fa-46e7-bd9e-6159ce6e27be", "d69f50b4-c207-4c43-903e-9acd02e9c392", "a4408110-3196-40bd-8b09-6cd9012762e1", "9bcfdd72-e566-43bc-ba00-88f6d1a24064", "70091946-07df-4e1b-ae40-550f67a0b2e9", "e165a69c-36b1-41a8-af08-661e0ddb4ce2"], "metadata": {"window": "The dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "The dial-in number for the live call will be (844) 808-6694. ", "page_label": "5", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "84eac33e-a33c-4491-92d8-95e95fe53864": {"node_ids": ["1f9fb7af-9747-4709-b93d-5341bd64c0a9", "ed99e983-27cb-4134-b209-c20d8867fdce", "c353602a-d05a-4da8-8802-4cb019f258bc", "a7af88a5-8758-4465-8187-7b96ffa71bc1", "bfed1781-bd80-4dfd-bd41-9b05a3718727", "4a8428db-e65a-49bb-8bcb-1b0093c86637"], "metadata": {"window": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the\nCompany, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services\narrangement; managing foreign expansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws,\neconomic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative\ninitiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of\nchallenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major\nsupplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity;\nchanges to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed;\nrisks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other\nunexpected events that affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and\ncomplete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its\npast practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic\ntransactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency\nof the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with\nemployees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance\nHealthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or\ncontrol, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the\nexpected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fc7aef28-971c-436a-be01-5362f39dd466": {"node_ids": ["bf42674f-7fcc-4894-bd3b-f40409f5684f"], "metadata": {"window": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "original_text": "Employee severance, litigation, and other 2 \u00a070,381 \u00a0\u00a0\u00a0\u00a0 \u00a039,309 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0905,002 \u00a0\u00a0\u00a01.72 %\u00a0967,777 \u00a0\u00a02.02 %\u00a0(6.5 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0547,228 \u00a0\u00a0\u00a01.04 %\u00a0263,437 \u00a0\u00a00.55 %\u00a0107.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 3 \u00a0(14,268 )\u00a0\u00a0\u00a0 \u00a02,842 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a033,614 \u00a0\u00a0\u00a0\u00a0 \u00a031,007 \u00a0\u00a0\u00a0 \u00a08.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0527,882 \u00a0\u00a0\u00a01.01 %\u00a0229,588 \u00a0\u00a00.48 %\u00a0129.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0149,175 \u00a0\u00a0\u00a0\u00a0 \u00a043,020 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0378,707 \u00a0\u00a0\u00a00.72 %\u00a0186,568 \u00a0\u00a00.39 %\u00a0103.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(3,862 )\u00a0\u00a0\u00a0 \u00a01,072 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$374,845 \u00a0\u00a0\u00a00.71 %\u00a0$187,640 \u00a0\u00a00.39 %\u00a099.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.83 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0101.1 %\nDiluted \u00a0$1.81 \u00a0\u00a0\u00a0\u00a0 \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0101.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,683 \u00a0\u00a0\u00a0\u00a0 \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0(0.6 )%\nDiluted \u00a0206,801 \u00a0\u00a0\u00a0\u00a0 \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e890ed33-efcd-4274-8eac-0080349b36c1": {"node_ids": ["a63e6680-ccce-4a5b-8dae-c8f387a1bddb", "f42c8119-4ec9-4c9f-a7d1-d48704ef12d8", "daa67c4e-9122-4a5c-a37c-500f10fa8ccb", "e025f58a-f885-4d76-b95f-f50a1ebc1d3f", "bbe54f4e-acfb-4093-80ec-67f9f21e6eac", "e2a6226f-273f-4013-b375-9a3c4dcb88b4", "19af3282-8035-4007-9576-d25c930021c9"], "metadata": {"window": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020.  Includes a $13.3 million LIFO expense, an\n$8.5 million gain from antitrust litigation settlements, and $7.1 million of PharMEDium remediation costs in the three months\nended December 31, 2019.\n 2\u00a0Includes $32.1 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits and\ninvestigations and $38.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, other restructuring initiatives in the three months ended December 31, 2020.  Includes $0.8 million of\nemployee severance, $24.7 million of litigation and opioid-related costs related to legal fees in connection with opioid lawsuits\nand investigations, and $13.8 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2019.\n", "original_text": "________________________________________\n1\u00a0Includes a $25.7 million LIFO credit in the three months ended December 31, 2020. ", "page_label": "8", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e4a6b124-21f7-4ecf-97d0-33b1f78e44de": {"node_ids": ["2822c04b-080f-4470-9eb3-f0395d7a9b8f", "c531f7a0-9fc1-49eb-ba67-1e06b863ceb2", "4486f55e-e8c9-4041-9dc7-a9d01cc49f2f", "7c514b4d-8591-4437-855f-b64c3acadc2a", "3f39011c-4fd3-48dc-b849-e05cfdf7b170"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a014.8 % \u00a08.3 % \u00a024.6 % \u00a026.5 % \u00a032.5 % \u00a0\u00a0 \u00a023.5 % \u00a023.9 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.77% \u00a02.72%\nOperating expenses \u00a01.72% \u00a01.54%\nOperating income \u00a01.04% \u00a01.17%\n________________________________________\n1\u00a0Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n 2\u00a0Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss.\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(14,039 )\u00a0(52,318 )\u00a0\u2014 \u00a0\u00a038,279 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,426,503 \u00a0\u00a0$809,587 \u00a0\u00a0$616,916 \u00a0\u00a0$583,531 \u00a0\u00a0$128,376 \u00a0\u00a0$(4,299 )\u00a0$450,856 \u00a0\u00a0$2.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "9", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "eec2445c-cf61-4e0c-a8f6-0696315e2372": {"node_ids": ["746b0dcd-4cf3-46a5-a942-05df0ebc517c"], "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nTaxes \u00a0Tax\nExpense \u00a0Noncontr olling\nInterest \u00a0Attributable\nto ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0\u00a0$967,777 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0$229,588 \u00a0\u00a0\u00a0$43,020 \u00a0\u00a0\u00a0$1,072 \u00a0\u00a0\u00a0$187,640 \u00a0\u00a0\u00a0$0.90\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,492 )\u00a0\u00a0(8,492 )\u00a0\u00a0(1,974 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,518 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a013,281 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a013,281 \u00a0\u00a0\u00a03,087 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,194 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135 \u00a0\u00a0\u00a0(9,030 )\u00a0\u00a016,165 \u00a0\u00a0\u00a016,165 \u00a0\u00a0\u00a03,757 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,408 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(33,566 )\u00a0\u00a033,566 \u00a0\u00a0\u00a033,566 \u00a0\u00a0\u00a07,801 \u00a0\u00a0\u00a0(436 )\u00a0\u00a025,329 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(39,309 )\u00a0\u00a039,309 \u00a0\u00a0\u00a039,309 \u00a0\u00a0\u00a09,136 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a030,173 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0138,000 \u00a0\u00a0\u00a0138,000 \u00a0\u00a0\u00a032,071 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0105,929 \u00a0\u00a0\u00a00.51 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,243,138 \u00a0\u00a0\u00a0$747,872 \u00a0\u00a0\u00a0$495,266 \u00a0\u00a0\u00a0$461,417 \u00a0\u00a0\u00a0$96,898 \u00a0\u00a0\u00a0$636 \u00a0\u00a0\u00a0$365,155 \u00a0\u00a0\u00a0$1.76\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n10", "page_label": "10", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0f62ec19-fd05-455f-addb-ba03898826c4": {"node_ids": ["1cb8bbc7-5258-486a-bae8-040bcb738fa7", "ee3a9dcd-544b-42fa-8436-60d4a50fdccb"], "metadata": {"window": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$50,492,510 \u00a0\u00a0\u00a0$46,036,828 \u00a0\u00a0\u00a09.7 %\nOther \u00a02,052,274 \u00a0\u00a0\u00a01,846,984 \u00a0\u00a0\u00a011.1 %\nIntersegment eliminations \u00a0(28,228 )\u00a0\u00a0(19,070 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$52,516,556 \u00a0\u00a0\u00a0$47,864,742 \u00a0\u00a0\u00a09.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$496,067 \u00a0\u00a0\u00a0$391,694 \u00a0\u00a0\u00a026.6 %\nOther \u00a0121,647 \u00a0\u00a0\u00a0104,479 \u00a0\u00a0\u00a016.4 %\nIntersegment eliminations \u00a0(798 )\u00a0\u00a0(907 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0616,916 \u00a0\u00a0\u00a0495,266 \u00a0\u00a0\u00a024.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a08,492 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a025,727 \u00a0\u00a0\u00a0(13,281 )\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(16,165 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,034 )\u00a0\u00a0(33,566 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(70,381 )\u00a0\u00a0(39,309 )\u00a0\u00a0\u00a0\n11", "original_text": "________________________________________\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "11", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "905f0978-1ca4-4ec8-b37d-9be865985c83": {"node_ids": ["0186fe30-ba76-4ed2-a63f-9ce90a282e03", "2f22a854-b0b3-41ec-8742-fc1a908e36b3"], "metadata": {"window": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Impairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(138,000 )\u00a0\u00a0\u00a0\nOperating income \u00a0$547,228 \u00a0\u00a0\u00a0$263,437 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.06 \u00a0%\u00a01.94 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.08 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.85 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.88 \u00a0%\u00a019.01 \u00a0%\u00a0\u00a0\nOperating expenses \u00a012.95 \u00a0%\u00a013.35 \u00a0%\u00a0\u00a0\nOperating income \u00a05.93 \u00a0%\u00a05.66 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.77 \u00a0%\u00a02.57 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.72 \u00a0%\u00a02.02 \u00a0%\u00a0\u00a0\nOperating income \u00a01.04 \u00a0%\u00a00.55 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72 \u00a0%\u00a02.60 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.54 \u00a0%\u00a01.56 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.17 \u00a0%\u00a01.03 \u00a0%\u00a0\u00a0\n\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1c2f3d50-6806-4b33-9c9e-674d04e0c4e9": {"node_ids": ["a86f974c-1137-45d1-a550-b5984c307bbf"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2020 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $4,890,918 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,886,252 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 13,178,958 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,191,767 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 317,656 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 234,670 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 34,700,221 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,477,040 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,571,661 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 326,820 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 771,026 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $33,449,690 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,535,390 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bc8e7659-908c-4294-9764-5ea7ec58ac51": {"node_ids": ["f84d4c7e-2b9b-4ed4-b89d-ca5c20a0d8d2"], "metadata": {"window": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "original_text": "Short-term debt 59,371 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 35,044,451 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,640,741 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 287,244 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 703,646 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 483,291 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,198,943 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (511,548 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $45,846,768 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Three Months Ended December 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $378,707 \u00a0\u00a0\u00a0$186,568 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1234,717 \u00a0\u00a0\u00a0341,020 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (906,495 )\u00a0\u00a0(307,204 )\u00a0\nInventories (545,459 )\u00a0\u00a0(630,980 )\u00a0\nAccounts payable 1,721,495 \u00a0\u00a0\u00a0787,037 \u00a0\u00a0\nOther, net 20,088 \u00a0\u00a0\u00a0(233,631 )\u00a0\nNet cash provided by operating activities 903,053 \u00a0\u00a0\u00a0142,810 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b8f69e19-0d12-45de-8d0f-502d5ea5015b": {"node_ids": ["6815612f-ae64-4430-83f4-fb5986dff386", "5c1b1223-6b4c-4773-adf2-533bf8f8b890", "cf9c1c70-c9ed-4a92-8759-25342e2b7646", "cb46ada3-e5a6-423c-9d44-5355478b35de", "a061a161-e183-44aa-80b2-6d40d309cb23", "e5a96f39-f34f-4082-9af7-3a6c6a23ff9d", "62e0b680-88bc-4940-9ef5-d81b34db8b38"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n 2\u00a0Purchases of common stock in the three months ended December 31, 2020 excludes $5.8 million of December 2020 purchases\nthat cash settled in January 2021.  Purchases of common stock in the three months ended December 31, 2019 includes $14.8\nmillion of September 2019 purchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases\nthat cash settled in January 2020.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (65,410 )\u00a0\u00a0(67,305 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a04,966 \u00a0\u00a0\nNet cash used in investing activities (65,410 )\u00a0\u00a0(62,339 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (431,250 )\u00a0\u00a0(13,981 )\u00a0\nPurchases of common stock 2 (56,175 )\u00a0\u00a0(135,128 )\u00a0\nExercises of stock options 58,216 \u00a0\u00a0\u00a020,113 \u00a0\u00a0\nCash dividends on common stock (91,103 )\u00a0\u00a0(83,088 )\u00a0\nOther (24,159 )\u00a0\u00a0(9,977 )\u00a0\nNet cash used in financing activities (544,471 )\u00a0\u00a0(222,061 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash and cash equivalents 293,172 \u00a0\u00a0\u00a0(141,590 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $4,890,918 \u00a0\u00a0\u00a0$3,232,604 \u00a0\u00a0\n________________________________________\n1\u00a0Includes a $138.0 million impairment of PharMEDium assets in the three months ended December 31, 2019.\n", "page_label": "15", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "af28ec91-33fa-4dc4-af17-9a2f6d4b857c": {"node_ids": ["0a34a9eb-058e-4aea-9e7b-e3e7638ead5b", "8893fa00-3af8-42e7-85b6-30bfaa87a7c6", "3ff58101-ede1-444d-a9a5-dc233958d615", "83c7e74d-0b9d-42d6-946f-80396d8cf8f5", "dadeb5da-8514-4d83-b336-cca43c918eba", "ec448e0e-572d-4f64-afaa-e70c12c282aa", "89797d9e-4f9e-4c5e-a52a-bd91cf318fc3", "a75d4af2-4a48-4d61-b575-c4b00c8e3670", "c5e810e9-b36a-428e-800c-4b6d1e809017", "991a55fc-751a-4c88-a743-c100c0be8581", "7f7ec767-b846-40f4-b379-ebac435a6bc1", "aa2b849e-3be6-4f6c-8b61-5d5502ef56d1", "6d1d27f1-3816-4b1a-a937-9af0cce13bb9", "e6856b82-cd85-4e6c-84fb-167c8a794668", "f6980210-6d86-4e4d-a93c-3f1ace73c07d", "425df418-507c-4cd9-8cdd-b83fcad6a616", "8c6e57bf-4883-4410-92f6-ad3113ab280b", "b0d87a1d-ea02-46f5-a774-5338ea943afb", "be542bb2-4949-474b-a001-f20f55bce10f", "9e1677e3-4e65-44d4-be26-2e51ada0077d", "b8615859-1b92-4f9f-b4c2-b2525cac831e", "e42a445b-bb21-4e87-862f-efefeb9aa399", "9d186b80-cde7-4802-a1df-d352a9d47bef", "677c71d0-f3a7-41bc-b088-74c61af5243e", "3ee12c98-a69c-4fca-990f-d3e1124df261", "7ed7bc3a-f046-496d-b8e4-892b60951963", "676181bd-cda9-42e7-a030-6d29a57569ca", "69e69e26-3fe1-4489-b6a6-e1c34513b742", "ef70dfe5-9037-40cd-9e61-b01d9d748c55", "b290d85b-1104-443f-894d-0aea6aa5e45e"], "metadata": {"window": "not be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "not be comparable to, similarly titled measures by other companies.\n", "page_label": "16", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5d1a4d54-4eb1-4c29-b6ab-e8401ee31647": {"node_ids": ["7e3062a1-03e2-4518-9cec-79e7256a1583", "9e24a6d4-3ee7-48f0-9942-93a20dec49ef", "ec9b0eb8-26d9-437a-8835-472f5a021aea", "2ab35f04-9d59-407d-9f7b-ceb35f015cad", "cd4993d6-a274-444a-9795-0db2a8a545fb", "0423de06-9bc8-4ac1-9358-12a4a9510762", "94b3f73c-a767-4b40-9fe2-00ac453781e5", "88514407-b707-4431-bb63-da1a2873d59d", "3b0b016c-f6ce-4b74-a65c-c9d721fef8c1", "92d32585-782f-4b7f-ac90-9607966cebee", "62744edf-e546-4d2c-9ebc-e8d628868d75", "ec740c97-cace-494a-8d9a-0ce19846920a", "bc187a50-349b-4346-8432-add0b6d2c20c", "ddcdbdfc-b991-4c9a-bda3-ebe80bdc0fa6", "0848b7e2-467b-4f9c-a280-d44b4d04eae2", "5ccb0794-34ca-4ae7-bf5c-4ddceed16d9a", "1911e64b-b2b9-4f27-82bf-c4f80e458c77"], "metadata": {"window": "2020.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income\nattributable to ABC.\n", "original_text": "2020. ", "page_label": "17", "file_name": "CEN-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 191096, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}